

Reference Section B
prevalence of reported esrd



table b.1 · 297

point prevalent counts of reported esrd patients
patients alive on december 31 of each year, by demographic characteristics & primary diagnosis

table b.2 · 298

period prevalent counts of reported esrd patients: all patients
patients alive during the calendar year, by demographic characteristics & primary diagnosis

table b.3 · 299

point prevalent counts of reported esrd patients: u.s. only, with unknowns dropped
patients alive on december 31 of each year, by demographic characteristics & primary diagnosis

table b.4 · 300

point prevalent rates of reported esrd, unadjusted
per million population, patients alive on december 31 of each year, by demographic characteristics & primary diagnosis

table b.5 · 301

point prevalent rates of reported esrd, adjusted
per million population, patients alive on december 31 of each year, by demographic characteristics, adjusted for age, gender, race, & ethnicity

table b.6 · 302

point prevalent counts of reported esrd patients: by time period
patients alive on december 31 of each year; grouped by age, gender, & race

table b.7 · 303

point prevalent rates of reported esrd: 1995-1997
per million population, patients alive on december 31 of each year; adjusted for & grouped by age, gender, & race

table b.8 · 303

point prevalent rates of reported esrd: 1998-2000
per million population, patients alive on december 31 of each year; adjusted for & grouped by age, gender, & race

table b.9 · 304

point prevalent counts of reported esrd patients: by primary diagnosis
1997-2000 combined, patients alive on december 31 of each year, by age; grouped by gender, & race

table b.10 · 307

point prevalent rates of reported esrd: by primary diagnosis
per ten million population, patients alive on december 31 of each year, 1997-2000 combined, adjusted for & grouped by age, gender, & race

table b.11 · 310

point prevalent counts of reported esrd patients, by diabetic status & state/territory: all patients
patients alive on december 31 of each year

table b.12 · 313

point prevalent counts of reported esrd patients, by diabetic status & state: u.s. only, with unknowns dropped
patients alive on december 31 of each year

table b.13 · 316

point prevalent rates of reported esrd: by diabetic status & state
per million population, patients alive on december 31 of each year; adjusted for age, gender, & race

table b.14 · 319

point prevalent counts of reported esrd patients, by diabetic status & esrd network: all patients
all patients alive on december 31 of each year

table b.15 · 320

point prevalent counts of reported esrd patients, by diabetic status & esrd network: u.s. only, with unknowns dropped
patients alive on december 31 of each year

table b.16 · 321

point prevalent rates of reported esrd: by diabetic status & esrd network
patients alive on december 31 of each year

Table B.1

Point Prevalent Counts of Reported ESRD Patients*patients alive on December 31 of each year; by demographic characteristics & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	357	383	412	456	471	499	467	482	519	603
5-9	757	761	799	839	868	877	933	908	940	909
10-14	1,208	1,279	1,342	1,446	1,556	1,624	1,619	1,711	1,737	1,793
15-19	2,360	2,415	2,544	2,746	2,891	2,952	3,053	3,118	3,197	3,255
20-24	4,901	5,191	5,307	5,556	5,597	5,604	5,533	5,671	5,806	5,958
25-29	8,666	8,900	9,095	9,555	9,896	10,174	10,280	10,466	10,402	10,242
30-34	12,917	13,591	14,391	15,394	15,911	15,942	15,827	15,913	16,011	16,361
35-39	15,805	17,078	18,071	19,835	20,901	21,680	22,085	22,711	23,257	23,532
40-44	17,656	19,237	20,807	22,702	24,646	25,958	27,008	28,274	29,441	30,144
45-49	16,974	19,051	21,279	24,388	27,223	29,554	30,800	32,671	34,169	36,028
50-54	16,807	19,024	21,071	24,179	26,291	28,867	31,353	34,266	37,558	40,774
55-59	18,288	20,105	21,972	24,728	26,998	29,104	31,635	34,416	36,796	39,041
60-64	20,677	22,345	23,963	26,641	29,124	31,225	33,059	35,386	37,283	39,118
65-69	22,023	24,582	26,826	29,386	31,181	33,187	34,663	36,122	37,680	38,999
70-74	18,696	21,280	23,551	26,601	28,461	30,423	32,490	34,002	35,003	36,185
75-79	12,680	14,343	15,752	18,093	20,096	22,458	24,663	26,635	28,421	29,816
80-84	6,499	7,700	8,736	10,048	11,136	12,312	13,549	14,657	15,663	17,416
85+	2,603	3,090	3,644	4,215	4,813	5,558	6,266	7,134	7,975	8,617
Unknown	77	79	71	80	76	76	59	60	63	71
0-19	4,682	4,838	5,097	5,487	5,786	5,952	6,072	6,219	6,393	6,560
20-44	59,945	63,997	67,671	73,042	76,951	79,358	80,733	83,035	84,917	86,237
45-64	72,746	80,525	88,285	99,936	109,636	118,750	126,847	136,739	145,806	154,961
65-74	40,719	45,862	50,377	55,987	59,642	63,610	67,153	70,124	72,683	75,184
75+	21,782	25,133	28,132	32,356	36,045	40,328	44,478	48,426	52,059	55,849
Unknown	77	79	71	80	76	76	59	60	63	71
Male	108,509	119,276	129,674	143,767	155,123	166,247	176,301	187,319	197,560	207,516
Female	91,432	101,144	109,936	123,045	132,927	141,724	148,987	157,241	164,330	171,307
Unknown	10	14	23	76	86	103	54	43	31	39
White	125,333	137,182	147,476	161,560	172,479	182,967	194,337	205,439	216,694	227,627
Black	63,207	70,106	76,817	85,551	93,245	100,643	106,552	112,909	117,766	121,945
Native American	2,662	3,089	3,411	3,859	4,385	4,936	5,049	5,594	5,744	5,861
Asian	6,040	6,850	7,887	9,191	10,464	11,564	12,400	13,419	14,296	15,121
Other/unknown	2,709	3,207	4,042	6,727	7,563	7,964	7,004	7,242	7,421	8,308
†Hispanic					18,821	24,459	29,158	33,326	36,801	40,383
†Non-Hispanic					269,315	283,615	296,184	311,277	325,120	338,479
Diabetes	51,393	59,239	65,405	74,904	84,889	95,523	105,955	115,452	123,345	131,173
Hypertension	47,711	53,682	57,808	64,369	67,742	71,837	75,664	79,900	83,586	86,739
Glomerulonephritis	36,499	39,266	41,746	44,936	47,991	50,803	53,304	55,806	57,797	59,056
Cystic kidney	9,615	10,394	11,039	11,888	12,701	13,360	14,017	14,889	15,669	16,298
Other urologic	3,698	4,145	4,440	4,817	5,301	5,873	6,324	6,728	7,149	7,387
Other cause	24,493	25,977	27,177	29,245	32,177	34,534	36,739	38,918	40,901	42,578
Unknown cause	9,366	9,970	10,292	11,012	11,450	12,140	12,695	13,404	13,969	14,631
Missing disease	17,176	17,761	21,726	25,717	25,885	24,004	20,644	19,506	19,505	21,000
U.S.	194,592	214,145	232,152	254,573	276,303	297,274	317,914	337,520	354,889	371,813
U.S. territories	182	229	247	266	323	382	438	471	519	541
Puerto Rico	2,228	2,486	2,647	2,915	3,072	3,325	3,506	3,664	3,802	3,932
Foreign	177	215	253	303	318	343	360	380	392	401
Unknown	2,772	3,359	4,334	8,831	8,120	6,750	3,124	2,568	2,319	2,175
All	199,951	220,434	239,633	266,888	288,136	308,074	325,342	344,603	361,921	378,862
Total lost-to-followup	7,412	8,260	9,271	10,409	11,839	14,874	21,407	26,608	32,610	40,973
Lost-to-followup & all	207,363	228,694	248,904	277,297	299,975	322,948	346,749	371,211	394,531	419,835

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table B.2

Period Prevalent Counts of Reported ESRD Patients: All Patients*patients alive during the calendar year, by demographic characteristics & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	496	505	555	577	640	675	701	660	691	773
5-9	858	879	905	971	996	1,022	1,019	1,075	1,084	1,103
10-14	1,417	1,453	1,527	1,614	1,741	1,845	1,918	1,904	2,021	2,058
15-19	2,783	2,863	2,940	3,126	3,331	3,495	3,510	3,602	3,733	3,817
20-24	5,565	5,920	6,175	6,431	6,636	6,656	6,582	6,571	6,653	6,881
25-29	10,037	10,264	10,566	11,053	11,258	11,609	11,898	12,042	12,175	12,246
30-34	14,151	15,163	15,928	17,187	17,990	18,415	18,387	18,350	18,421	18,658
35-39	17,411	18,696	19,933	21,753	23,255	24,314	25,072	25,511	26,238	26,791
40-44	19,042	21,081	22,665	24,966	26,923	29,032	30,266	31,675	32,944	34,408
45-49	18,189	20,680	23,050	26,315	29,483	32,642	35,023	36,726	38,854	40,715
50-54	19,060	21,040	23,466	26,862	29,862	32,144	35,290	38,399	41,947	45,734
55-59	21,194	23,451	25,429	28,740	31,400	33,913	36,534	39,730	43,067	46,020
60-64	25,321	27,351	29,251	32,182	34,993	37,667	40,200	42,607	45,140	47,560
65-69	27,695	30,599	33,468	36,768	39,037	41,457	43,942	45,667	47,257	49,132
70-74	23,091	26,785	29,801	33,290	36,260	39,090	41,629	44,072	45,925	47,295
75-79	16,214	18,663	20,628	23,051	25,488	28,499	31,743	34,731	37,715	39,918
80-84	8,303	9,718	11,118	12,812	14,329	16,067	18,028	19,633	21,396	23,047
85+	3,244	3,876	4,569	5,315	6,053	7,045	8,161	9,382	10,694	11,862
Unknown	90	91	87	100	87	80	82	67	72	95
0-19	5,554	5,700	5,927	6,288	6,708	7,037	7,148	7,241	7,529	7,751
20-44	66,206	71,124	75,267	81,390	86,062	90,026	92,205	94,149	96,431	98,984
45-64	83,764	92,522	101,196	114,099	125,738	136,366	147,047	157,462	169,008	180,029
65-74	50,786	57,384	63,269	70,058	75,297	80,547	85,571	89,739	93,182	96,427
75+	27,761	32,257	36,315	41,178	45,870	51,611	57,932	63,746	69,805	74,827
Unknown	90	91	87	100	87	80	82	67	72	95
Male	126,767	139,870	152,142	168,190	182,184	196,538	209,803	222,600	236,205	249,133
Female	107,383	119,192	129,895	144,837	157,484	169,021	180,074	189,744	199,772	208,941
Unknown	11	16	24	86	94	108	108	60	50	39
White	148,440	163,448	175,997	192,215	206,195	219,760	234,845	249,040	263,947	278,242
Black	73,039	81,047	89,118	99,056	108,310	117,402	125,116	132,725	139,673	145,306
Native American	3,037	3,539	3,925	4,421	5,047	5,733	5,921	6,472	6,738	6,966
Asian	6,680	7,632	8,704	10,254	11,731	13,224	14,265	15,489	16,648	17,580
Other/unknown	2,965	3,412	4,317	7,167	8,479	9,548	9,838	8,678	9,021	10,019
†Hispanic					20,506	27,784	33,539	39,187	43,693	48,067
†Non-Hispanic					319,256	337,883	356,446	373,217	392,334	410,046
Diabetes	62,942	72,783	80,618	91,528	103,966	117,550	130,881	143,786	155,170	165,117
Hypertension	58,042	65,433	70,667	78,268	82,766	87,473	93,196	98,323	103,771	108,152
Glomerulonephritis	40,098	43,091	45,770	49,228	52,656	56,226	59,022	61,695	64,122	65,899
Cystic kidney	10,383	11,245	11,978	12,838	13,780	14,578	15,326	16,155	17,051	17,813
Other urologic	4,282	4,874	5,199	5,621	6,160	6,861	7,372	7,881	8,396	8,779
Other cause	28,100	29,875	31,318	33,680	37,309	40,752	43,496	46,283	48,922	51,345
Unknown cause	11,033	11,933	12,262	12,875	13,614	14,446	15,299	16,128	16,890	17,810
Missing disease	19,281	19,844	24,249	29,075	29,511	27,781	25,393	22,153	21,705	23,198
U.S.	228,022	252,035	273,685	299,613	326,037	352,635	377,991	403,693	427,575	449,667
U.S. territories	216	268	295	324	371	444	525	580	609	664
Puerto Rico	2,658	2,953	3,171	3,504	3,769	4,026	4,296	4,554	4,778	4,908
Foreign	196	230	269	320	343	362	387	410	410	429
Unknown	3,069	3,592	4,641	9,352	9,242	8,200	6,786	3,167	2,655	2,445
All	234,161	259,078	282,061	313,113	339,762	365,667	389,985	412,404	436,027	458,113

The period prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the period prevalent patient is determined as of December 31 of the selected calendar year.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table B.3

Point Prevalent Counts of Reported ESRD Patients: U.S. Only, with Unknowns dropped*patients alive on December 31 of each year, by demographic characteristics & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	326	354	383	392	401	426	416	427	471	553
5-9	683	689	725	760	793	800	860	832	849	830
10-14	1,127	1,180	1,232	1,314	1,424	1,489	1,494	1,594	1,624	1,665
15-19	2,207	2,265	2,372	2,527	2,663	2,746	2,860	2,919	2,999	3,036
20-24	4,610	4,859	4,981	5,107	5,194	5,238	5,218	5,347	5,467	5,576
25-29	8,231	8,446	8,550	8,807	9,170	9,486	9,718	9,928	9,883	9,688
30-34	12,380	13,012	13,757	14,376	14,910	14,973	15,070	15,154	15,270	15,572
35-39	15,132	16,386	17,321	18,577	19,645	20,508	21,175	21,831	22,357	22,577
40-44	16,945	18,399	19,811	21,198	23,106	24,498	25,952	27,263	28,411	29,009
45-49	16,227	18,214	20,318	22,871	25,669	27,989	29,476	31,336	32,867	34,634
50-54	16,121	18,185	20,083	22,547	24,642	27,239	29,959	32,862	36,100	39,241
55-59	17,594	19,271	20,944	23,080	25,257	27,386	30,172	32,947	35,278	37,421
60-64	20,090	21,661	23,059	25,062	27,459	29,544	31,667	33,971	35,840	37,545
65-69	21,616	24,051	26,158	28,365	29,992	31,915	33,557	34,984	36,500	37,755
70-74	18,396	20,848	23,045	25,824	27,626	29,525	31,699	33,181	34,189	35,289
75-79	12,516	14,144	15,488	17,630	19,572	21,877	24,172	26,126	27,878	29,242
80-84	6,401	7,603	8,586	9,778	10,843	12,005	13,327	14,437	15,426	17,165
85+	2,562	3,032	3,572	4,080	4,660	5,392	6,151	7,031	7,847	8,490
0-19	4,343	4,488	4,712	4,993	5,281	5,461	5,630	5,772	5,943	6,084
20-44	57,298	61,102	64,420	68,065	72,025	74,703	77,133	79,523	81,388	82,422
45-64	70,032	77,331	84,404	93,560	103,027	112,158	121,274	131,116	140,085	148,841
65-74	40,012	44,899	49,203	54,189	57,618	61,440	65,256	68,165	70,689	73,044
75+	21,479	24,779	27,646	31,488	35,075	39,274	43,650	47,594	51,151	54,897
Male	104,633	114,934	124,702	136,365	147,346	158,373	169,491	180,332	190,248	199,523
Female	88,531	97,665	105,683	115,930	125,680	134,663	143,452	151,838	159,008	165,765
White	122,393	133,860	143,753	156,176	167,395	178,218	190,620	201,802	212,998	223,862
Black	62,357	69,137	75,713	83,623	91,374	98,921	105,412	111,881	116,783	121,028
Native American	2,635	3,060	3,379	3,785	4,320	4,880	5,019	5,573	5,723	5,841
Asian	5,779	6,542	7,540	8,711	9,937	11,017	11,892	12,914	13,752	14,557
†Hispanic					15,665	20,032	23,656	27,262	30,257	33,180
†Non-Hispanic					257,361	273,004	289,287	304,908	318,999	332,108
Diabetes	50,271	57,772	63,609	72,189	81,721	91,913	102,340	111,754	119,480	127,008
Hypertension	47,075	52,865	56,751	62,595	65,857	69,911	74,013	78,220	81,923	84,998
Glomerulonephritis	35,603	38,288	40,662	43,557	46,461	49,166	51,702	54,119	56,031	57,170
Cystic kidney	9,487	10,244	10,862	11,634	12,433	13,051	13,740	14,588	15,357	15,946
Other urologic	3,619	4,058	4,330	4,662	5,131	5,688	6,151	6,559	6,958	7,188
Other cause	24,126	25,549	26,656	28,416	31,267	33,585	35,913	38,057	40,001	41,584
Unknown cause	9,126	9,699	9,980	10,551	10,946	11,620	12,247	12,923	13,481	14,088
Missing disease	13,857	14,124	17,535	18,691	19,210	18,102	16,837	15,950	16,025	17,306
All	193,164	212,599	230,385	252,295	273,026	293,036	312,943	332,170	349,256	365,288
Patients dropped	6,787	7,835	9,248	14,593	15,110	15,038	12,399	12,433	12,665	13,574

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality r
The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

U.S. only; unknown age, gender, & race; other & unknown are excluded.

Table B.4

Point Prevalent Rates of Reported ESRD, Unadjusted*per million population, patients alive on December 31 of each year; by demographic characteristics & primary diagnosis*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	17	18	19	20	21	22	22	23	25	29
5-9	37	38	39	40	41	41	43	42	43	42
10-14	63	64	66	70	75	78	78	82	82	83
15-19	128	131	135	141	144	145	148	149	151	152
20-24	241	257	268	281	293	299	297	300	299	298
25-29	403	425	442	463	485	503	520	540	548	548
30-34	558	585	620	654	691	712	737	760	777	798
35-39	727	767	795	839	876	908	936	967	998	1,020
40-44	902	968	1,018	1,061	1,125	1,161	1,200	1,235	1,266	1,273
45-49	1,102	1,164	1,246	1,340	1,431	1,517	1,580	1,640	1,675	1,718
50-54	1,360	1,468	1,549	1,680	1,788	1,873	1,940	2,043	2,142	2,221
55-59	1,683	1,821	1,938	2,097	2,251	2,370	2,498	2,607	2,694	2,765
60-64	1,912	2,096	2,270	2,491	2,740	2,946	3,116	3,270	3,385	3,498
65-69	2,161	2,407	2,618	2,852	3,025	3,244	3,465	3,675	3,868	4,010
70-74	2,202	2,441	2,656	2,940	3,136	3,367	3,613	3,777	3,904	4,043
75-79	1,974	2,196	2,370	2,654	2,880	3,131	3,381	3,593	3,782	3,924
80-84	1,565	1,811	1,993	2,213	2,395	2,600	2,838	3,024	3,174	3,471
85+	788	897	1,019	1,126	1,245	1,398	1,545	1,710	1,853	1,949
0-19	60	61	63	66	69	71	73	74	76	77
20-44	565	603	636	672	712	739	764	789	807	817
45-64	1,473	1,580	1,680	1,815	1,945	2,055	2,152	2,252	2,329	2,397
65-74	2,180	2,422	2,636	2,893	3,077	3,302	3,535	3,724	3,886	4,026
75+	1,570	1,768	1,927	2,144	2,328	2,540	2,758	2,945	3,107	3,277
Male	846	919	986	1,068	1,143	1,217	1,290	1,359	1,420	1,475
Female	682	744	797	866	930	988	1,042	1,094	1,136	1,174
White	578	626	667	719	765	808	858	902	945	986
Black	1,985	2,165	2,334	2,542	2,742	2,930	3,081	3,229	3,329	3,407
Native American	1,237	1,411	1,533	1,691	1,901	2,114	2,142	2,342	2,368	2,378
Asian	711	768	849	944	1,037	1,107	1,154	1,213	1,245	1,266
†Hispanic					568	699	796	885	948	1,005
†Non-Hispanic					1,089	1,148	1,209	1,267	1,318	1,364
Diabetes	198	225	246	276	310	345	380	412	436	459
Hypertension	186	206	219	239	249	262	275	288	299	307
Glomerulonephritis	140	149	157	167	176	184	192	199	205	207
Cystic kidney	37	40	42	44	47	49	51	54	56	58
Other urologic	14	16	17	18	19	21	23	24	25	26
Other cause	95	100	103	109	118	126	133	140	146	150
Unknown cause	36	38	39	40	41	44	46	48	49	51
Missing disease	55	55	68	71	73	68	63	59	58	63
All	762	829	889	965	1,034	1,100	1,163	1,224	1,275	1,321

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

Table B.5

Point Prevalent Rates of Reported ESRD, Adjusted*per million population, patients alive on December 31 of each year; by demographic characteristics, adjusted for age, gender, race, & ethnicity*

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	17	18	19	20	20	22	21	22	24	29
5-9	37	37	38	39	40	40	43	41	42	41
10-14	62	64	66	69	74	76	76	81	81	82
15-19	126	129	132	137	140	141	143	144	147	148
20-24	237	251	261	273	283	289	286	289	289	287
25-29	399	420	436	456	476	492	507	524	529	529
30-34	559	586	620	653	688	706	728	749	765	786
35-39	737	776	801	844	880	911	937	965	994	1,013
40-44	939	1,000	1,047	1,089	1,152	1,185	1,219	1,250	1,277	1,281
45-49	1,190	1,258	1,341	1,433	1,523	1,601	1,653	1,707	1,735	1,772
50-54	1,475	1,595	1,691	1,836	1,954	2,056	2,128	2,227	2,318	2,386
55-59	1,858	2,007	2,134	2,302	2,466	2,599	2,743	2,872	2,968	3,045
60-64	2,166	2,366	2,547	2,780	3,046	3,266	3,441	3,609	3,720	3,818
65-69	2,504	2,766	3,007	3,245	3,421	3,646	3,862	4,070	4,259	4,394
70-74	2,607	2,890	3,168	3,509	3,748	3,990	4,235	4,396	4,483	4,589
75-79	2,395	2,664	2,891	3,238	3,493	3,783	4,052	4,298	4,505	4,651
80-84	2,017	2,345	2,566	2,837	3,060	3,319	3,589	3,813	3,971	4,295
85+	1,133	1,281	1,428	1,567	1,713	1,948	2,106	2,307	2,477	2,581
0-19	60	62	64	66	69	70	71	72	74	75
20-44	574	607	633	663	696	716	735	755	771	779
45-64	1,672	1,806	1,928	2,088	2,247	2,381	2,491	2,604	2,685	2,755
65-74	2,556	2,828	3,087	3,377	3,584	3,818	4,048	4,233	4,371	4,491
75+	1,848	2,097	2,295	2,547	2,755	3,017	3,249	3,473	3,651	3,842
Male	960	1,037	1,107	1,192	1,266	1,339	1,407	1,470	1,524	1,569
Female	676	733	781	844	902	951	996	1,038	1,070	1,098
White	576	622	660	708	751	789	833	871	908	943
Black	2,634	2,866	3,081	3,337	3,566	3,781	3,944	4,097	4,180	4,240
Native American	1,843	2,111	2,277	2,490	2,772	3,052	3,049	3,309	3,304	3,287
Asian	964	1,037	1,139	1,262	1,383	1,468	1,514	1,572	1,598	1,623
†Hispanic					873	1,089	1,242	1,378	1,465	1,540
†Non-Hispanic					1,074	1,126	1,178	1,226	1,268	1,304
Diabetes	210	237	257	287	320	354	387	415	436	456
Hypertension	201	221	233	252	260	271	281	291	299	304
Glomerulonephritis	147	156	163	172	180	188	195	201	205	205
Cystic kidney	40	43	45	47	49	51	52	54	56	57
Other urologic	15	16	17	18	20	22	23	24	25	26
Other cause	97	102	105	110	120	127	134	141	146	150
Unknown cause	38	40	40	42	43	45	46	48	49	51
Missing disease	58	58	71	74	75	70	64	59	58	62
All (crude)	762	829	889	965	1,034	1,100	1,163	1,224	1,275	1,321
All (adjusted)	806	872	930	1,002	1,068	1,127	1,182	1,234	1,275	1,311

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

Table B.6
Point Prevalent Counts of Reported ESRD Patients: by Time Period
patients alive on December 31 of each year; grouped by age, gender, & race

1995-1997	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	598	154	6	21	779	346	96	6	16	464	944	250	12	37	1,243
5-9	1,213	299	22	34	1,568	690	138	18	39	885	1,903	437	40	73	2,453
10-14	1,969	589	36	88	2,682	1,286	338	24	77	1,725	3,255	927	60	165	4,407
15-19	3,211	1,276	60	153	4,700	2,424	897	72	176	3,569	5,635	2,173	132	329	8,269
20-29	14,916	8,310	327	965	24,518	11,950	6,403	311	842	19,506	26,866	14,713	638	1,807	44,024
30-39	38,351	19,648	761	2,013	60,773	28,183	14,710	708	1,907	45,508	66,534	34,358	1,469	3,920	106,281
40-49	54,319	34,695	1,472	3,051	93,537	36,591	22,584	1,085	2,893	63,153	90,910	57,279	2,557	5,944	156,690
50-59	53,607	33,194	1,842	3,357	92,000	39,607	28,428	1,752	2,868	72,655	93,214	61,622	3,594	6,225	164,655
60-64	27,494	15,526	786	1,672	45,478	22,953	17,738	990	1,511	43,192	50,447	33,264	1,776	3,183	88,670
65-69	30,419	13,938	671	1,598	46,626	27,172	18,891	944	1,831	48,838	57,591	32,829	1,615	3,429	95,464
70-79	55,474	17,656	708	2,702	76,540	46,436	27,267	1,193	3,035	77,931	101,910	44,923	1,901	5,737	154,471
80+	20,078	4,775	146	1,010	26,009	16,946	8,157	279	987	26,369	37,024	12,932	425	1,997	52,378
0-19	6,991	2,318	124	296	9,729	4,746	1,469	120	308	6,643	11,737	3,787	244	604	16,372
20-44	79,280	43,930	1,724	4,448	129,382	57,446	31,454	1,457	4,122	94,479	136,726	75,384	3,181	8,570	223,861
45-64	109,407	67,443	3,464	6,610	186,924	81,838	58,409	3,389	5,899	149,535	191,245	125,852	6,853	12,509	336,459
65-74	61,215	24,725	1,112	3,169	90,221	53,374	35,434	1,691	3,594	94,093	114,589	60,159	2,803	6,763	184,314
75+	44,756	11,644	413	2,141	58,954	37,180	18,881	725	2,259	59,045	81,936	30,525	1,138	4,400	117,999
All	301,649	150,060	6,837	16,664	475,210	234,584	145,647	7,382	16,182	403,795	536,233	295,707	14,219	32,846	879,005
1998-2000															
0-4	702	175	3	28	908	414	111	5	13	543	1,116	286	8	41	1,451
5-9	1,143	311	18	39	1,511	743	207	15	35	1,000	1,886	518	33	74	2,511
10-14	2,141	592	54	76	2,863	1,480	426	24	90	2,020	3,621	1,018	78	166	4,883
15-19	3,526	1,363	58	181	5,128	2,589	985	59	193	3,826	6,115	2,348	117	374	8,954
20-29	15,264	8,718	347	1,108	25,437	11,965	7,102	361	1,024	20,452	27,229	15,820	708	2,132	45,889
30-39	39,478	22,064	774	2,283	64,599	28,701	16,683	734	2,044	48,162	68,179	38,747	1,508	4,327	112,761
40-49	63,233	40,389	1,674	3,689	108,985	42,484	27,225	1,293	3,533	74,535	105,717	67,614	2,967	7,222	183,520
50-59	71,184	43,337	2,439	4,319	121,279	51,480	34,898	2,234	3,958	92,570	122,664	78,235	4,673	8,277	213,849
60-64	33,894	18,732	1,131	2,236	55,993	27,756	20,443	1,200	1,964	51,363	61,650	39,175	2,331	4,200	107,356
65-69	35,291	16,426	789	2,072	54,578	30,367	20,904	1,191	2,199	54,661	65,658	37,330	1,980	4,271	109,239
70-79	68,101	20,700	863	3,421	93,085	55,952	31,627	1,369	3,872	92,820	124,053	52,327	2,232	7,293	185,905
80+	28,127	6,058	176	1,376	35,737	22,647	10,216	326	1,470	34,659	50,774	16,274	502	2,846	70,396
0-19	7,512	2,441	133	324	10,410	5,226	1,729	103	331	7,389	12,738	4,170	236	655	17,799
20-44	84,493	48,765	1,863	5,048	140,169	60,721	36,108	1,646	4,689	103,164	145,214	84,873	3,509	9,737	243,333
45-64	138,560	84,475	4,502	8,587	236,124	101,665	70,243	4,176	7,834	183,918	240,225	154,718	8,678	16,421	420,042
65-74	71,518	28,650	1,360	3,933	105,461	60,680	39,366	2,011	4,380	106,437	132,198	68,016	3,371	8,313	211,898
75+	60,001	14,534	468	2,936	77,939	48,286	23,381	875	3,161	75,703	108,287	37,915	1,343	6,097	153,642
All	362,084	178,865	8,326	20,828	570,103	276,578	170,827	8,811	20,395	476,611	638,662	349,692	17,137	41,223	1,046,714

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the point prevalent patient is determined as of December 31 of the selected calendar year. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

Table B.7

Point Prevalent Rates of Reported ESRD: 1995-1997

per million population, patients alive on December 31 of each year; adjusted for & grouped by age, gender, & race

1995-1997	Unadjusted rates								Rates adjusted for							
	Males				Females				gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	26	35	*	16	16	22	*	13	20	28	20	14	26	16	21	
5-9	51	63	64	28	31	30	54	34	41	46	59	31	52	31	41	
10-14	85	132	99	74	58	78	68	67	71	105	83	70	90	61	75	
15-19	138	285	183	136	111	207	223	161	124	245	205	149	157	126	141	
20-29	335	1,090	566	408	277	793	567	333	303	939	566	368	436	345	389	
30-39	711	2,480	1,384	789	528	1,641	1,287	678	615	2,048	1,336	733	943	681	808	
40-49	1,098	5,496	3,410	1,448	735	3,067	2,378	1,209	919	4,346	2,961	1,341	1,720	1,079	1,389	
50-59	1,625	9,394	7,270	2,739	1,146	6,417	6,324	2,092	1,395	7,970	6,936	2,454	2,744	1,932	2,324	
60-64	2,207	12,050	9,330	4,115	1,680	10,318	10,301	3,052	1,937	11,160	9,820	3,565	3,605	2,916	3,251	
65-69	2,567	11,662	10,241	5,054	1,956	11,791	11,984	4,190	2,256	11,726	11,129	4,605	3,900	3,395	3,643	
70-79	3,062	11,878	8,124	6,509	1,914	12,130	10,566	5,406	2,476	11,875	9,244	5,991	4,369	3,415	3,884	
80+	2,632	8,174	3,921	6,134	1,096	6,492	4,206	4,502	1,781	7,165	4,049	5,071	3,348	1,929	2,623	
0-19	75	128	92	61	53	84	92	66	64	106	92	66	81	59	70	
20-44	635	2,302	1,263	733	467	1,491	1,079	621	531	1,896	1,199	672	844	595	716	
45-64	1,596	8,878	6,524	2,560	1,142	6,180	5,868	1,992	1,437	8,072	6,855	2,499	2,767	2,003	2,373	
65-74	2,761	11,979	9,435	5,602	1,970	12,361	11,793	4,634	2,365	12,239	10,575	5,169	4,137	3,507	3,817	
75+	2,901	9,689	5,733	6,483	1,402	8,430	6,325	5,110	2,013	8,443	5,522	5,464	3,687	2,356	3,007	
All	929	3,123	1,994	1,158	696	2,736	2,112	1,047	811	2,919	2,053	1,101	1,217	987	1,099	
All (age adjusted)	959	4,273	2,959	1,632	652	3,288	2,933	1,312	791	3,763	2,958	1,455	1,337	950	1,126	

Table B.8

Point Prevalent Rates of Reported ESRD: 1998-2000

per million population, patients alive on december 31 of each year; adjusted for & grouped by age, gender, & race

1998-2000	Unadjusted rates								Rates adjusted for							
	Male				Female				gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	30	41	*	20	19	27	*	10	24	34	*	15	31	19	25	
5-9	48	66	55	28	33	45	47	27	40	55	51	28	49	34	41	
10-14	90	124	141	59	65	92	65	74	77	108	102	67	93	69	81	
15-19	145	293	163	144	114	219	167	157	129	255	165	151	164	129	146	
20-29	347	1,118	582	449	281	864	625	388	314	1,000	607	412	455	363	408	
30-39	767	2,813	1,386	807	562	1,887	1,350	665	656	2,327	1,366	736	1,028	738	879	
40-49	1,207	5,731	3,565	1,526	808	3,349	2,631	1,308	1,010	4,609	3,151	1,434	1,848	1,182	1,504	
50-59	1,892	10,629	8,488	2,910	1,311	6,839	7,113	2,333	1,615	8,852	7,982	2,695	3,156	2,150	2,636	
60-64	2,598	13,684	12,414	4,662	1,951	11,124	11,447	3,542	2,266	12,374	11,917	4,088	4,185	3,273	3,716	
65-69	3,095	13,657	11,482	5,818	2,306	12,935	14,231	4,654	2,693	13,287	12,886	5,220	4,632	3,867	4,241	
70-79	3,647	13,046	8,948	7,196	2,292	13,527	11,207	5,807	2,961	13,246	9,937	6,540	5,053	3,940	4,487	
80+	3,333	9,565	4,020	6,904	1,390	7,737	4,188	5,217	2,283	8,495	4,160	5,894	4,142	2,378	3,241	
0-19	79	132	96	61	58	97	77	65	68	113	83	65	84	63	73	
20-44	685	2,494	1,319	764	500	1,680	1,186	655	566	2,065	1,282	696	902	643	768	
45-64	1,844	9,842	7,626	2,800	1,298	6,599	6,487	2,236	1,657	8,906	7,930	2,790	3,162	2,231	2,681	
65-74	3,289	13,428	11,000	6,242	2,328	13,418	13,295	5,077	2,804	13,435	12,089	5,697	4,780	3,965	4,365	
75+	3,579	11,273	5,487	7,326	1,737	9,988	6,608	5,662	2,524	9,967	5,635	6,231	4,487	2,858	3,655	
All	1,090	3,577	2,319	1,301	804	3,092	2,406	1,187	944	3,322	2,363	1,242	1,419	1,135	1,273	
All (age adjusted)	1,108	4,753	3,332	1,789	744	3,631	3,244	1,443	907	4,172	3,300	1,598	1,521	1,069	1,273	

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

*Values for cells with fewer than 10 patients are suppressed.

Table B.9
Point Prevalent Counts of Reported ESRD Patients: by Primary Diagnosis
 1997-2000 combined, patients alive on December 31 of each year, by age; grouped by gender & race

DIABETES	Male				Female				Gender				Race		Gender
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	& Race
0-4	25	*	.	*	36	29	24	*	.	54	54	33	*	*	90
5-9	*	*	.	.	*	*	*	.	.	*	*	*	.	.	15
10-14	*	*	.	.	*	.	*	.	.	*	*	15	.	.	17
15-19	14	14	.	.	28	23	19	.	.	42	37	33	.	.	70
20-29	1,455	660	15	23	2,153	1,614	1,024	53	45	2,736	3,069	1,684	68	68	4,889
30-39	14,581	3,601	251	263	18,696	10,765	3,665	263	289	14,982	25,346	7,266	514	552	33,678
40-49	28,003	9,408	970	966	39,347	18,427	8,682	834	654	28,597	46,430	18,090	1,804	1,620	67,944
50-59	34,988	17,985	2,025	2,084	57,082	25,493	20,145	2,090	1,523	49,251	60,481	38,130	4,115	3,607	106,333
60-64	17,707	10,150	976	1,236	30,069	16,955	14,339	1,191	1,216	33,701	34,662	24,489	2,167	2,452	63,770
65-69	18,235	9,128	682	1,249	29,294	19,329	14,995	1,182	1,440	36,946	37,564	24,123	1,864	2,689	66,240
70-79	27,983	10,286	663	1,773	40,705	30,628	20,569	1,265	2,480	54,942	58,611	30,855	1,928	4,253	95,647
80+	6,478	1,989	93	541	9,101	7,245	4,657	233	653	12,788	13,723	6,646	326	1,194	21,889
0-19	47	30	.	*	79	55	57	*	.	113	102	87	*	*	192
20-44	29,022	7,719	621	652	38,014	20,845	7,947	636	568	29,996	49,867	15,666	1,257	1,220	68,010
45-64	67,712	34,085	3,616	3,920	109,333	52,409	39,908	3,795	3,159	99,271	120,121	73,993	7,411	7,079	208,604
65-74	34,664	15,565	1,142	2,258	53,629	37,202	27,616	1,963	2,885	69,666	71,866	43,181	3,105	5,143	123,295
75+	18,032	5,838	296	1,305	25,471	20,000	12,605	717	1,688	35,010	38,032	18,443	1,013	2,993	60,481
All	149,477	63,237	5,675	8,137	226,526	130,511	88,133	7,112	8,300	234,056	279,988	151,370	12,787	16,437	460,582
HYPERTENSION															
0-4	14	11	.	.	25	19	26	.	.	45	33	37	.	.	70
5-9	18	*	.	.	26	23	*	*	.	33	41	15	*	.	59
10-14	25	*	.	.	28	32	16	*	*	51	57	19	*	.	79
15-19	63	129	*	*	199	88	72	*	*	174	151	201	10	11	373
20-29	1,427	3,231	55	187	4,900	900	1,561	71	85	2,617	2,327	4,792	126	272	7,517
30-39	4,660	10,499	139	488	15,786	2,383	5,423	79	341	8,226	7,043	15,922	218	829	24,012
40-49	8,473	22,380	306	923	32,082	4,088	11,185	198	696	16,167	12,561	33,565	504	1,619	48,249
50-59	11,618	22,015	401	1,029	35,063	6,827	13,076	213	923	21,039	18,445	35,091	614	1,952	56,102
60-64	7,467	8,694	154	631	16,946	4,640	7,333	128	449	12,550	12,107	16,027	282	1,080	29,496
65-69	10,274	7,794	115	631	18,814	6,729	7,993	135	647	15,504	17,003	15,787	250	1,278	34,318
70-79	29,359	10,926	193	1,418	41,896	19,403	14,737	273	1,254	35,667	48,762	25,663	466	2,672	77,563
80+	16,466	3,959	60	767	21,252	12,644	6,540	106	774	20,064	29,110	10,499	166	1,541	41,316
0-19	120	151	*	*	278	162	121	11	*	303	282	272	16	11	581
20-44	9,955	23,640	338	1,099	35,032	5,108	11,994	231	712	18,045	15,063	35,634	569	1,811	53,077
45-64	23,690	43,179	717	2,159	69,745	13,730	26,584	458	1,782	42,554	37,420	69,763	1,175	3,941	112,299
65-74	24,399	13,965	224	1,338	39,926	15,856	16,035	273	1,302	33,466	40,255	30,000	497	2,640	73,392
75+	31,700	8,714	144	1,478	42,036	22,920	13,235	241	1,373	37,769	54,620	21,949	385	2,851	79,805
All	89,864	89,649	1,428	6,076	187,017	57,776	67,969	1,214	5,178	132,137	147,640	157,618	2,642	11,254	319,154
GLOMERULONEPHRITIS															
0-4	44	17	.	*	69	41	*	.	*	55	85	23	.	16	124
5-9	218	49	*	13	285	232	53	*	14	304	450	102	10	27	589
10-14	489	143	24	26	682	489	192	11	38	730	978	335	35	64	1,412
15-19	1,105	649	19	84	1,857	970	505	33	101	1,609	2,075	1,154	52	185	3,466
20-29	6,882	4,112	191	703	11,888	5,005	2,985	193	547	8,730	11,887	7,097	384	1,250	20,618
30-39	15,192	7,188	341	1,400	24,121	9,239	5,178	319	1,059	15,795	24,431	12,366	660	2,459	39,916
40-49	20,277	9,430	485	1,741	31,933	11,454	5,774	326	1,842	19,396	31,731	15,204	811	3,583	51,329
50-59	17,722	6,367	340	1,353	25,782	9,891	3,889	254	1,236	15,270	27,613	10,256	594	2,589	41,052
60-64	7,033	1,820	127	479	9,459	3,929	1,505	105	369	5,908	10,962	3,325	232	848	15,367
65-69	6,465	1,401	100	352	8,318	3,938	1,283	103	287	5,611	10,403	2,684	203	639	13,929
70-79	11,438	1,693	101	610	13,842	6,770	1,776	95	546	9,187	18,208	3,469	196	1,156	23,029
80+	4,000	443	23	196	4,662	2,773	521	34	201	3,529	6,773	964	57	397	8,191
0-19	1,856	858	48	131	2,893	1,732	756	49	161	2,698	3,588	1,614	97	292	5,591
20-44	32,118	16,010	774	2,961	51,863	19,860	11,044	675	2,588	34,167	51,978	27,054	1,449	5,549	86,030
45-64	34,988	12,907	710	2,715	51,320	19,658	8,287	522	2,465	30,932	54,646	21,194	1,232	5,180	82,252
65-74	12,875	2,426	154	693	16,148	7,688	2,324	158	599	10,769	20,563	4,750	312	1,292	26,917
75+	9,028	1,111	70	465	10,674	5,793	1,256	74	435	7,558	14,821	2,367	144	900	18,232
All	90,865	33,312	1,756	6,965	132,898	54,731	23,667	1,478	6,248	86,124	145,596	56,979	3,234	13,213	219,022

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.
 The age of the point prevalent patient is determined as of December 31 of the selected calendar year.
 U.S. only; unknown age, gender, & race; other & unknown are excluded.
 *Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table B.9 (continued)

Point Prevalent Counts of Reported ESRD Patients: by Primary Diagnosis

1997-2000 combined, patients alive on December 31 of each year, by age; grouped by gender & race

CYSTIC KIDNEY	Male				Females				Gender				Race		Gender & Race
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	
0-4	57	11	.	*	69	71	*	.	.	73	128	13	.	*	142
5-9	94	13	*	*	111	91	10	*	*	110	185	23	*	*	221
10-14	138	28	*	*	177	162	11	*	*	178	300	39	10	*	355
15-19	194	39	*	*	243	171	41	*	26	240	365	80	*	30	483
20-29	470	62	12	19	563	537	57	*	24	619	1,007	119	13	43	1,182
30-39	1,411	214	21	42	1,688	1,102	242	18	30	1,392	2,513	456	39	72	3,080
40-49	5,818	786	58	176	6,838	3,841	882	42	131	4,896	9,659	1,668	100	307	11,734
50-59	9,148	1,079	78	270	10,575	7,606	1,320	41	204	9,171	16,754	2,399	119	474	19,746
60-64	3,332	451	14	100	3,897	3,320	481	35	98	3,934	6,652	932	49	198	7,831
65-69	2,576	290	18	79	2,963	2,802	391	13	67	3,273	5,378	681	31	146	6,236
70-79	2,793	401	*	86	3,287	3,282	483	*	90	3,864	6,075	884	16	176	7,151
80+	569	121	.	22	712	638	106	*	12	758	1,207	227	*	34	1,470
0-19	483	91	16	10	600	495	64	*	35	601	978	155	23	45	1,201
20-44	4,037	556	56	125	4,774	3,021	622	35	101	3,779	7,058	1,178	91	226	8,553
45-64	16,142	2,036	127	482	18,787	13,385	2,360	102	386	16,233	29,527	4,396	229	868	35,020
65-74	4,341	536	24	137	5,038	4,843	693	18	133	5,687	9,184	1,229	42	270	10,725
75+	1,597	276	*	50	1,924	1,879	287	*	36	2,208	3,476	563	*	86	4,132
All	26,600	3,495	224	804	31,123	23,623	4,026	168	691	28,508	50,223	7,521	392	1,495	59,631
OTHER UROLOGIC															
0-4	21	*	.	.	26	*	.	.	.	*	27	*	.	.	32
5-9	69	31	.	*	104	34	12	.	.	46	103	43	.	*	150
10-14	173	53	*	10	237	122	19	.	*	143	295	72	*	12	380
15-19	332	65	.	15	412	224	32	*	*	267	556	97	*	22	679
20-29	1,144	258	*	30	1,441	984	88	14	15	1,101	2,128	346	23	45	2,542
30-39	1,567	306	41	56	1,970	1,420	109	30	40	1,599	2,987	415	71	96	3,569
40-49	1,643	328	30	56	2,057	1,458	237	*	74	1,776	3,101	565	37	130	3,833
50-59	1,426	340	23	59	1,848	1,401	275	15	99	1,790	2,827	615	38	158	3,638
60-64	972	205	16	46	1,239	668	135	*	41	848	1,640	340	20	87	2,087
65-69	1,127	299	12	44	1,482	663	125	*	39	833	1,790	424	18	83	2,315
70-79	2,973	580	28	72	3,653	1,166	207	15	94	1,482	4,139	787	43	166	5,135
80+	1,607	226	16	42	1,891	467	108	*	28	605	2,074	334	18	70	2,496
0-19	595	154	*	29	779	386	63	*	*	462	981	217	*	38	1,241
20-44	3,540	732	72	112	4,456	3,175	324	51	90	3,640	6,715	1,056	123	202	8,096
45-64	3,212	705	47	135	4,099	2,756	520	19	179	3,474	5,968	1,225	66	314	7,573
65-74	2,524	620	29	91	3,264	1,245	252	14	96	1,607	3,769	872	43	187	4,871
75+	3,183	485	27	67	3,762	1,051	188	*	65	1,313	4,234	673	36	132	5,075
All	13,054	2,696	176	434	16,360	8,613	1,347	97	439	10,496	21,667	4,043	273	873	26,856
UNKNOWN CAUSE															
0-4	30	*	.	*	35	14	*	.	*	19	44	*	.	*	54
5-9	79	12	*	*	93	39	13	.	.	52	118	25	*	*	145
10-14	115	41	*	*	165	127	55	*	12	198	242	96	*	17	363
15-19	220	133	*	13	367	290	82	*	15	388	510	215	*	28	755
20-29	1,439	644	32	99	2,214	993	397	22	89	1,501	2,432	1,041	54	188	3,715
30-39	2,471	1,416	57	201	4,145	1,864	787	57	149	2,857	4,335	2,203	114	350	7,002
40-49	3,139	2,039	85	242	5,505	2,432	1,157	56	215	3,860	5,571	3,196	141	457	9,365
50-59	2,928	1,548	54	199	4,729	2,201	1,016	51	276	3,544	5,129	2,564	105	475	8,273
60-64	1,380	623	17	116	2,136	1,209	561	32	101	1,903	2,589	1,184	49	217	4,039
65-69	1,695	530	33	104	2,362	1,270	557	23	83	1,933	2,965	1,087	56	187	4,295
70-79	4,067	859	54	172	5,152	2,796	967	52	210	4,025	6,863	1,826	106	382	9,177
80+	2,557	360	*	90	3,012	1,912	500	30	102	2,544	4,469	860	35	192	5,556
0-19	444	188	*	22	660	470	154	*	28	657	914	342	11	50	1,317
20-44	5,444	3,130	131	435	9,140	4,041	1,706	94	325	6,166	9,485	4,836	225	760	15,306
45-64	5,913	3,140	114	422	9,589	4,658	2,212	124	505	7,499	10,571	5,352	238	927	17,088
65-74	3,620	1,029	66	187	4,902	2,681	1,098	60	186	4,025	6,301	2,127	126	373	8,927
75+	4,699	720	26	179	5,624	3,297	926	45	209	4,477	7,996	1,646	71	388	10,101
All	20,120	8,207	343	1,245	29,915	15,147	6,096	328	1,253	22,824	35,267	14,303	671	2,498	52,739

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

The age of the point prevalent patient is determined as of December 31 of the selected calendar year.

U.S. only; unknown age, gender, & race; other & unknown are excluded.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table B.9 (continued)
Point Prevalent Counts of Reported ESRD Patients: by Primary Diagnosis
 1997-2000 combined, patients alive on December 31 of each year, by age; grouped by gender & race

OTHER CAUSE	Male				Female				Gender				Race		Gender & Race
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	
0-4	624	150	*	23	802	290	71	*	10	377	914	221	11	33	1,179
5-9	830	229	14	21	1,094	396	129	10	18	553	1,226	358	24	39	1,647
10-14	1,393	387	28	43	1,851	743	192	11	52	998	2,136	579	39	95	2,849
15-19	2,106	603	40	90	2,839	1,240	384	27	83	1,734	3,346	987	67	173	4,573
20-29	5,899	1,801	131	258	8,089	4,663	2,591	110	418	7,782	10,562	4,392	241	676	15,871
30-39	8,906	3,985	150	340	13,381	8,347	5,223	168	560	14,298	17,253	9,208	318	900	27,679
40-49	9,386	5,402	185	346	15,319	9,388	5,544	164	624	15,720	18,774	10,946	349	970	31,039
50-59	7,964	3,186	136	276	11,562	8,642	3,103	151	496	12,392	16,606	6,289	287	772	23,954
60-64	3,870	1,025	84	133	5,112	3,697	1,141	29	161	5,028	7,567	2,166	113	294	10,140
65-69	4,235	805	38	125	5,203	3,784	966	48	155	4,953	8,019	1,771	86	280	10,156
70-79	8,435	1,267	50	209	9,961	7,230	1,394	61	237	8,922	15,665	2,661	111	446	18,883
80+	3,509	438	19	97	4,063	2,893	542	17	70	3,522	6,402	980	36	167	7,585
0-19	4,953	1,369	87	177	6,586	2,669	776	54	163	3,662	7,622	2,145	141	340	10,248
20-44	19,553	8,469	387	755	29,164	17,813	10,826	354	1,277	30,270	37,366	19,295	741	2,032	59,434
45-64	16,472	6,930	299	598	24,299	16,924	6,776	268	982	24,950	33,396	13,706	567	1,580	49,249
65-74	8,720	1,509	77	251	10,557	7,714	1,775	93	297	9,879	16,434	3,284	170	548	20,436
75+	7,459	1,001	30	180	8,670	6,193	1,127	33	165	7,518	13,652	2,128	63	345	16,188
All	57,157	19,278	880	1,961	79,276	51,313	21,280	802	2,884	76,279	108,470	40,558	1,682	4,845	155,555
MISSING DISEASE															
0-4	82	18	.	*	102	58	15	.	*	74	140	33	.	*	176
5-9	237	78	*	13	330	172	34	.	*	215	409	112	*	22	545
10-14	465	122	*	15	604	249	57	.	12	318	714	179	*	27	922
15-19	621	179	*	20	824	400	165	*	20	591	1,021	344	10	40	1,415
20-29	1,578	799	13	129	2,519	1,262	601	12	97	1,972	2,840	1,400	25	226	4,491
30-39	3,607	1,657	44	196	5,504	3,087	1,204	43	232	4,566	6,694	2,861	87	428	10,070
40-49	5,553	3,055	62	318	8,988	4,144	1,956	41	326	6,467	9,697	5,011	103	644	15,455
50-59	5,183	2,935	66	269	8,453	3,871	2,231	61	266	6,429	9,054	5,166	127	535	14,882
60-64	1,982	1,262	26	113	3,383	1,556	1,243	26	85	2,910	3,538	2,505	52	198	6,293
65-69	1,416	1,139	*	80	2,643	1,297	1,214	15	138	2,664	2,713	2,353	23	218	5,307
70-79	1,459	976	14	52	2,501	1,354	1,234	26	76	2,690	2,813	2,210	40	128	5,191
80+	377	235	*	15	628	421	303	*	16	743	798	538	*	31	1,371
0-19	1,405	397	*	50	1,860	879	271	*	42	1,198	2,284	668	14	92	3,058
20-44	7,873	3,845	89	466	12,273	6,417	2,707	82	481	9,687	14,290	6,552	171	947	21,960
45-64	10,030	5,863	122	559	16,574	7,503	4,528	101	525	12,657	17,533	10,391	223	1,084	29,231
65-74	2,318	1,744	19	123	4,204	2,155	2,005	28	199	4,387	4,473	3,749	47	322	8,591
75+	934	606	*	24	1,568	917	746	16	31	1,710	1,851	1,352	20	55	3,278
All	22,560	12,455	242	1,222	36,479	17,871	10,257	233	1,278	29,639	40,431	22,712	475	2,500	66,118

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. The age of the point prevalent patient is determined as of December 31 of the selected calendar year. U.S. only; unknown age, gender, & race; other & unknown are excluded. *Values for cells with fewer than 10 patients are suppressed. "." Zero values in this cell.

Table B.10

Point Prevalent Rates of Reported ESRD: by Primary Diagnosis

per ten million population, patients alive on December 31 of each year, 1997-2000 combined, by primary diagnosis; adjusted for & grouped by age, gender, & race

DIABETES	Specific rates (unadjusted)								Rates adjusted for							
	Males				Females				Gender				Race			
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Gender & Race	
0-4	8	*	.	*	10	43	*	.	9	30	*	*	9	14	12	
5-9	*	*	.	.	*	*	.	.	*	*	.	.	*	*	2	
10-14	*	*	.	.	.	*	.	.	*	12	.	.	*	*	2	
15-19	4	23	.	.	8	32	.	.	6	27	.	.	6	10	8	
20-29	248	638	190	71	284	938	694	129	265	801	453	96	293	363	329	
30-39	2,108	3,435	3,380	711	1,569	3,099	3,621	716	1,802	3,244	3,501	716	2,195	1,731	1,958	
40-49	4,049	10,180	15,706	3,063	2,653	8,130	12,879	1,850	3,363	9,472	14,728	2,506	4,989	3,466	4,209	
50-59	7,115	33,886	53,918	10,857	4,963	30,316	50,904	6,963	6,109	33,169	53,977	9,299	11,374	8,930	10,122	
60-64	10,273	56,279	81,375	19,830	9,016	59,277	86,517	16,755	9,618	57,743	83,829	18,217	17,146	16,433	16,788	
65-69	11,920	56,947	75,094	26,802	10,914	69,656	107,037	23,114	11,420	63,433	91,288	24,878	18,850	19,783	19,349	
70-79	11,290	49,113	52,370	28,560	9,414	66,385	78,609	28,632	10,255	57,102	64,206	28,592	17,000	17,917	17,501	
80+	5,852	23,899	16,352	20,991	3,364	26,672	23,033	18,082	4,352	24,714	20,142	18,755	8,305	7,081	7,689	
0-19	4	12	.	*	5	24	*	.	4	19	*	*	5	7	6	
20-44	1,761	2,972	3,317	752	1,284	2,782	3,453	602	1,406	2,847	3,531	659	1,782	1,385	1,580	
45-64	6,862	30,396	46,739	9,851	5,095	28,676	45,001	6,943	6,416	34,220	52,872	10,040	11,484	9,621	10,532	
65-74	11,921	55,020	69,856	27,345	10,638	70,875	98,219	25,480	11,272	63,016	83,430	26,529	18,528	19,745	19,179	
75+	8,169	34,331	26,712	25,154	5,433	40,652	41,528	23,509	6,029	33,678	31,041	22,171	10,802	10,096	10,457	
All	3,387	9,547	11,946	3,880	2,855	12,036	14,679	3,684	3,116	10,854	13,326	3,778	4,248	4,197	4,222	
All (age adjusted)	3,408	13,700	18,199	5,842	2,620	14,670	20,706	4,898	2,988	14,285	19,646	5,336	4,560	3,933	4,235	
HYPERTENSION																
0-4	5	19	.	.	6	47	.	.	6	33	0	0	6	11	9	
5-9	6	*	.	.	8	*	*	.	7	12	*	0	6	8	7	
10-14	8	*	.	.	11	26	*	.	9	16	*	0	7	13	10	
15-19	20	209	*	*	29	121	*	*	24	164	108	35	44	43	43	
20-29	243	3,123	696	574	158	1,430	930	243	200	2,291	822	391	637	331	478	
30-39	674	10,015	1,872	1,320	347	4,586	1,088	845	503	7,188	1,470	1,079	1,893	910	1,382	
40-49	1,225	24,217	4,955	2,926	589	10,473	3,058	1,969	908	17,591	4,060	2,476	4,363	1,961	3,112	
50-59	2,362	41,479	10,677	5,361	1,329	19,678	5,188	4,220	1,875	30,675	7,918	4,965	7,664	3,900	5,704	
60-64	4,332	48,206	12,840	10,123	2,467	30,314	9,298	6,187	3,377	39,043	11,034	8,104	10,252	6,242	8,174	
65-69	6,716	48,624	12,662	13,541	3,799	37,130	12,225	10,385	5,228	42,748	12,432	11,902	12,410	8,408	10,350	
70-79	11,846	52,169	15,245	22,841	5,964	47,563	16,965	14,478	8,957	50,109	16,267	18,985	17,715	11,807	14,697	
80+	14,875	47,569	10,550	29,760	5,871	37,457	10,478	21,432	10,059	41,808	10,504	24,898	19,090	10,552	14,726	
0-19	9	62	*	*	13	51	62	*	11	56	44	9	16	19	17	
20-44	604	9,103	1,805	1,267	315	4,198	1,254	755	434	6,556	1,567	983	1,706	814	1,242	
45-64	2,401	38,505	9,268	5,426	1,335	19,102	5,431	3,917	2,045	30,438	7,935	5,252	7,710	4,094	5,829	
65-74	8,391	49,364	13,702	16,204	4,534	41,153	13,660	11,499	6,471	45,472	13,830	14,035	14,108	9,661	11,828	
75+	14,361	51,244	12,995	28,488	6,227	42,684	13,959	19,122	10,106	45,213	12,771	23,866	19,268	11,268	15,180	
All	2,036	13,535	3,006	2,897	1,264	9,282	2,506	2,298	1,643	11,302	2,753	2,587	3,507	2,369	2,925	
All (age adjusted)	2,167	18,454	4,502	4,507	1,086	11,194	3,498	3,098	1,548	14,668	3,996	3,715	3,946	2,153	2,939	
GLOMERULONEPHRITIS																
0-4	14	30	.	*	14	*	.	*	14	20	0	45	17	15	16	
5-9	68	77	*	72	76	86	*	83	72	82	115	78	70	78	74	
10-14	154	228	475	153	163	316	225	236	159	273	346	197	167	186	177	
15-19	343	1,051	405	510	321	847	710	626	332	947	561	568	441	404	422	
20-29	1,172	3,974	2,417	2,156	880	2,734	2,529	1,563	1,023	3,364	2,481	1,825	1,588	1,157	1,366	
30-39	2,196	6,857	4,592	3,786	1,346	4,379	4,392	2,624	1,754	5,584	4,487	3,194	2,867	1,810	2,324	
40-49	2,932	10,204	7,853	5,520	1,649	5,407	5,034	5,210	2,287	7,840	6,474	5,387	4,042	2,315	3,154	
50-59	3,604	11,996	9,053	7,048	1,926	5,853	6,186	5,651	2,753	8,778	7,632	6,356	4,865	2,611	3,705	
60-64	4,080	10,091	10,589	7,685	2,089	6,222	7,627	5,084	3,061	8,111	9,074	6,332	5,049	2,787	3,889	
65-69	4,226	8,740	11,011	7,554	2,224	5,960	9,327	4,607	3,204	7,319	10,153	6,051	4,999	2,861	3,905	
70-79	4,615	8,084	7,978	9,826	2,081	5,732	5,903	6,304	3,314	6,837	7,000	8,081	5,292	2,745	3,990	
80+	3,614	5,323	4,044	7,605	1,288	2,984	3,361	5,566	2,353	4,065	3,743	6,393	3,858	1,685	2,747	
0-19	146	350	262	188	144	318	274	240	144	330	255	222	174	171	172	
20-44	1,949	6,165	4,134	3,413	1,224	3,866	3,665	2,743	1,533	4,981	3,956	3,025	2,518	1,614	2,053	
45-64	3,546	11,510	9,177	6,823	1,911	5,955	6,190	5,418	2,757	8,584	7,860	6,183	4,796	2,625	3,680	
65-74	4,428	8,575	9,420	8,392	2,198	5,964	7,906	5,290	3,294	7,228	8,455	6,909	5,173	2,857	3,988	
75+	4,090	6,533	6,317	8,963	1,574	4,051	4,286	6,058	2,650	4,889	4,910	7,060	4,317	2,003	3,134	
All	2,059	5,029	3,696	3,321	1,197	3,232	3,050	2,773	1,621	4,086	3,370	3,037	2,492	1,544	2,008	
All (age adjusted)	2,069	5,906	4,704	3,928	1,151	3,480	3,626	3,008	1,579	4,647	4,139	3,432	2,600	1,503	2,013	

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table B.10 (continued)

Point Prevalent Rates of Reported ESRD: by Primary Diagnosis

per ten million population, patients alive on december 31 of each year, 1997-2000 combined, by primary diagnosis; adjusted for & grouped by age, gender, & race

CYSTIC KIDNEY	Specific rates (unadjusted)								Rates adjusted for							
	Males				Females				Gender				Race		Gender	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	& Race	
0-4	18	19	.	*	24	*	.	.	21	11	0	*	18	20	19	
5-9	29	20	*	*	30	16	*	*	30	18	*	*	28	29	28	
10-14	44	45	*	*	54	18	*	*	49	31	98	*	44	48	46	
15-19	60	63	*	*	57	69	*	161	58	66	*	95	60	62	61	
20-29	80	60	152	58	94	52	*	69	87	56	82	64	77	87	82	
30-39	204	204	283	114	161	205	248	74	178	202	265	94	197	161	179	
40-49	841	851	939	558	553	826	649	371	708	871	814	477	853	594	721	
50-59	1,860	2,033	2,077	1,407	1,481	1,986	999	933	1,688	2,037	1,532	1,192	1,888	1,542	1,712	
60-64	1,933	2,501	1,167	1,604	1,765	1,988	2,542	1,350	1,846	2,236	1,884	1,474	1,985	1,782	1,880	
65-69	1,684	1,809	1,982	1,695	1,582	1,816	1,177	1,075	1,633	1,813	1,565	1,375	1,704	1,589	1,645	
70-79	1,127	1,915	*	1,385	1,009	1,559	*	1,039	1,051	1,710	534	1,160	1,211	1,062	1,135	
80+	514	1,454	.	854	296	607	*	332	388	981	*	544	607	335	467	
0-19	38	37	87	14	41	27	*	52	40	32	59	35	37	40	39	
20-44	245	214	299	144	186	218	190	107	202	213	251	125	224	178	201	
45-64	1,636	1,816	1,642	1,211	1,301	1,696	1,210	848	1,540	1,875	1,503	1,126	1,724	1,415	1,566	
65-74	1,493	1,895	1,468	1,659	1,385	1,779	901	1,175	1,432	1,839	1,130	1,412	1,543	1,421	1,480	
75+	723	1,623	*	964	510	926	*	501	549	1,172	*	653	751	514	629	
All	603	528	472	383	517	550	347	307	559	539	409	344	584	511	547	
All (age adjusted)	600	724	605	499	487	642	440	356	541	677	522	422	607	498	549	
OTHER UROLOGIC																
0-4	7	*	.	.	*	.	.	.	4	*	.	.	7	*	4	
5-9	22	49	.	*	11	20	.	.	16	34	.	*	25	12	18	
10-14	55	84	*	59	41	31	.	*	47	57	*	35	58	38	48	
15-19	103	105	.	91	74	54	*	*	88	79	*	67	102	70	86	
20-29	195	249	*	92	173	81	183	43	184	164	150	66	197	156	176	
30-39	227	292	552	151	207	92	413	99	218	190	482	125	236	190	212	
40-49	238	355	486	178	210	222	*	209	224	289	277	196	253	210	231	
50-59	290	641	612	307	273	414	365	453	283	538	527	393	345	300	322	
60-64	564	1,137	1,334	738	355	558	*	565	457	840	796	654	651	388	516	
65-69	737	1,865	1,321	944	374	581	*	626	552	1,209	926	778	895	413	647	
70-79	1,200	2,769	2,212	1,160	358	668	932	1,085	782	1,705	1,547	1,109	1,429	433	918	
80+	1,452	2,716	2,813	1,630	217	619	*	775	809	1,642	1,451	1,198	1,611	292	935	
0-19	47	63	*	42	32	27	*	*	39	44	*	28	48	30	39	
20-44	215	282	385	129	196	113	277	95	204	196	336	110	221	180	200	
45-64	326	629	608	339	268	374	225	393	313	556	497	416	402	300	350	
65-74	868	2,192	1,774	1,102	356	647	700	848	610	1,430	1,267	996	1,069	418	735	
75+	1,442	2,852	2,437	1,291	286	606	*	905	838	1,681	1,463	1,133	1,613	342	961	
All	296	407	370	207	188	184	200	195	241	290	284	201	307	188	246	
All (age adjusted)	308	583	563	291	181	213	242	242	234	375	382	262	334	183	247	
UNKNOWN CAUSE																
0-4	10	*	.	*	5	*	.	*	7	*	.	*	9	5	7	
5-9	25	19	*	*	13	21	.	.	19	20	*	*	23	13	18	
10-14	36	65	*	*	42	91	*	75	39	78	*	53	40	50	45	
15-19	68	215	*	79	96	138	*	93	82	176	*	86	87	100	94	
20-29	245	622	405	304	175	364	288	254	209	494	347	279	298	203	249	
30-39	357	1,351	768	544	272	666	785	369	313	998	775	455	495	329	409	
40-49	454	2,206	1,376	767	350	1,083	865	608	403	1,648	1,141	691	703	463	579	
50-59	595	2,917	1,438	1,037	429	1,529	1,242	1,262	514	2,206	1,334	1,151	920	615	762	
60-64	801	3,454	1,417	1,861	643	2,319	2,325	1,392	720	2,877	1,890	1,630	1,189	903	1,041	
65-69	1,108	3,306	3,634	2,232	717	2,587	2,083	1,332	909	2,939	2,851	1,768	1,457	994	1,220	
70-79	1,641	4,102	4,265	2,771	859	3,121	3,231	2,424	1,258	3,605	3,655	2,686	2,054	1,238	1,637	
80+	2,310	4,326	*	3,492	888	2,864	2,966	2,824	1,564	3,543	2,040	3,110	2,563	1,235	1,884	
0-19	35	77	*	32	39	65	*	42	37	70	28	38	40	42	41	
20-44	330	1,205	700	501	249	597	510	345	282	892	614	417	448	293	368	
45-64	599	2,800	1,474	1,061	453	1,589	1,470	1,110	547	2,277	1,504	1,174	946	664	800	
65-74	1,245	3,637	4,037	2,265	767	2,818	3,002	1,643	1,005	3,259	3,593	1,964	1,631	1,091	1,354	
75+	2,129	4,234	2,346	3,450	896	2,986	2,606	2,911	1,514	3,573	2,352	3,144	2,477	1,253	1,851	
All	456	1,239	722	594	331	833	677	556	393	1,026	699	574	561	409	483	
All (age adjusted)	474	1,601	1,010	795	306	962	897	672	378	1,265	957	727	610	388	485	

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table B.10 (continued)

Point Prevalent Rates of Reported ESRD: by Primary Diagnosis

per ten million population, patients alive on December 31 of each year, 1997-2000 combined, by primary diagnosis; adjusted for & grouped by age, gender, & race

OTHER CAUSE	Specific rates (unadjusted)								Rates adjusted for							
	Males				Females				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	202	262	*	125	99	128	*	56	149	193	136	90	206	101	152	
5-9	259	361	316	117	130	210	233	107	193	284	275	113	267	140	202	
10-14	440	617	554	254	247	316	225	324	341	463	385	290	456	259	355	
15-19	654	977	852	546	410	644	581	514	529	806	714	531	693	446	566	
20-29	1,005	1,741	1,658	791	819	2,373	1,441	1,194	910	2,073	1,547	995	1,099	1,038	1,069	
30-39	1,287	3,801	2,020	919	1,216	4,417	2,313	1,388	1,249	4,103	2,168	1,161	1,599	1,638	1,620	
40-49	1,357	5,845	2,996	1,097	1,352	5,191	2,533	1,765	1,357	5,540	2,769	1,456	1,948	1,872	1,908	
50-59	1,619	6,003	3,621	1,438	1,683	4,670	3,678	2,268	1,666	5,280	3,711	1,881	2,196	2,117	2,154	
60-64	2,245	5,683	7,004	2,134	1,966	4,717	2,107	2,218	2,100	5,186	4,473	2,178	2,719	2,328	2,518	
65-69	2,768	5,022	4,184	2,682	2,137	4,487	4,347	2,488	2,447	4,748	4,261	2,587	3,067	2,472	2,763	
70-79	3,403	6,050	3,950	3,367	2,222	4,499	3,791	2,736	2,806	5,279	3,682	3,036	3,764	2,542	3,139	
80+	3,170	5,263	3,341	3,764	1,343	3,104	1,680	1,938	2,179	4,103	2,415	2,734	3,350	1,588	2,449	
0-19	391	558	475	254	222	327	302	243	303	437	378	256	405	236	319	
20-44	1,186	3,261	2,067	870	1,098	3,790	1,922	1,354	1,123	3,508	2,012	1,113	1,437	1,434	1,437	
45-64	1,669	6,180	3,865	1,503	1,645	4,869	3,178	2,158	1,712	5,409	3,701	1,900	2,304	2,122	2,209	
65-74	2,999	5,334	4,710	3,040	2,206	4,555	4,653	2,623	2,601	4,965	4,731	2,864	3,334	2,549	2,933	
75+	3,379	5,886	2,707	3,470	1,682	3,635	1,911	2,298	2,405	4,528	2,330	2,799	3,542	1,878	2,691	
All	1,295	2,910	1,852	935	1,123	2,906	1,655	1,280	1,207	2,908	1,753	1,114	1,486	1,368	1,426	
All (age adjusted)	1,313	3,453	2,268	1,143	1,075	3,100	1,940	1,361	1,179	3,255	2,095	1,242	1,555	1,330	1,427	
MISSING DISEASE																
0-4	27	31	.	*	20	27	.	*	23	29	.	*	26	20	23	
5-9	74	123	*	72	56	55	.	*	65	88	*	63	80	56	67	
10-14	147	194	*	88	83	94	.	75	114	143	*	81	150	83	116	
15-19	193	290	*	121	132	277	*	124	162	283	108	123	201	150	175	
20-29	269	772	165	396	222	551	157	277	244	664	161	328	339	265	301	
30-39	521	1,581	593	530	450	1,018	592	575	480	1,288	592	553	652	526	587	
40-49	803	3,306	1,004	1,008	597	1,832	633	922	700	2,607	808	974	1,148	773	954	
50-59	1,054	5,530	1,757	1,401	754	3,357	1,486	1,216	899	4,481	1,651	1,322	1,650	1,124	1,378	
60-64	1,150	6,997	2,168	1,813	827	5,139	1,889	1,171	984	6,066	2,020	1,475	1,936	1,404	1,661	
65-69	926	7,106	*	1,717	732	5,639	1,358	2,215	826	6,359	1,123	1,974	1,748	1,426	1,582	
70-79	589	4,660	1,106	838	416	3,983	1,616	877	494	4,261	1,355	788	1,111	886	995	
80+	341	2,824	*	582	195	1,735	*	443	266	2,248	*	524	660	406	528	
0-19	111	162	*	72	73	114	*	63	91	136	37	69	114	77	95	
20-44	478	1,481	475	537	395	948	445	510	418	1,204	472	514	594	456	523	
45-64	1,016	5,228	1,577	1,405	729	3,254	1,198	1,154	885	4,531	1,521	1,315	1,636	1,125	1,372	
65-74	797	6,165	1,162	1,490	616	5,146	1,401	1,758	700	5,555	1,308	1,585	1,492	1,239	1,362	
75+	423	3,564	*	463	249	2,406	927	432	316	2,755	566	476	769	510	635	
All	511	1,880	509	583	391	1,401	481	567	450	1,629	495	575	684	531	606	
All (age adjusted)	507	2,395	658	660	381	1,600	607	603	442	1,980	636	631	713	516	608	

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table B.11

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients*patients alive on December 31 of each year*

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	3,985	4,377	4,716	5,160	5,586	6,138	6,631	6,923	7,195	7,629
Alaska	178	210	234	402	632	607	534	392	400	421
Arizona	2,964	3,352	3,709	4,043	4,420	4,787	5,211	5,568	5,918	6,213
Arkansas	1,734	1,870	2,054	2,339	2,598	2,791	2,998	3,129	3,259	3,379
California	21,506	23,521	25,520	28,163	30,572	33,220	35,727	38,001	39,646	41,741
Colorado	1,872	2,095	2,318	2,544	2,690	2,897	3,126	3,367	3,539	3,685
Connecticut	2,423	2,620	2,783	3,068	3,292	3,534	3,753	3,886	4,029	4,228
Delaware	616	714	777	847	915	966	1,028	1,063	1,131	1,176
District of Columbia	1,043	1,164	1,252	1,296	1,423	1,512	1,621	1,660	1,763	1,812
Florida	11,222	12,493	13,530	14,608	15,713	17,166	18,298	19,234	19,878	20,594
Georgia	6,263	7,027	7,671	8,546	9,314	10,076	10,707	11,379	12,052	12,795
Hawaii	1,030	1,110	1,242	1,399	1,493	1,591	1,730	1,803	1,882	2,012
Idaho	551	590	643	714	762	841	926	975	1,075	1,096
Illinois	9,688	10,482	11,411	12,480	13,417	14,360	15,218	16,157	17,028	17,709
Indiana	3,968	4,407	4,788	5,038	5,579	5,957	6,367	6,841	7,210	7,637
Iowa	1,855	2,056	2,189	2,370	2,458	2,628	2,744	2,904	3,115	3,226
Kansas	1,651	1,789	1,856	2,037	2,174	2,313	2,520	2,653	2,799	2,885
Kentucky	2,505	2,807	3,038	3,115	3,465	3,702	3,953	4,192	4,421	4,615
Louisiana	4,059	4,499	4,842	5,284	5,807	6,233	6,819	7,295	7,781	8,138
Maine	640	687	761	846	937	997	1,071	1,151	1,178	1,240
Maryland	4,264	4,728	5,152	5,577	6,233	6,570	7,105	7,580	8,012	8,421
Massachusetts	4,020	4,439	4,794	5,223	5,570	5,889	6,267	6,605	6,612	6,830
Michigan	7,025	7,812	8,517	9,412	10,206	11,212	11,855	12,582	13,033	13,731
Minnesota	3,011	3,288	3,550	3,904	4,160	4,447	4,721	4,958	5,183	5,426
Mississippi	2,548	2,804	3,079	3,485	3,781	4,121	4,434	4,718	4,956	5,127
Missouri	4,047	4,368	4,756	5,196	5,599	5,998	6,346	6,790	7,143	7,413
Montana	489	520	572	618	688	724	783	818	878	912
Nebraska	998	1,136	1,207	1,341	1,441	1,505	1,626	1,716	1,827	1,919
Nevada	799	897	1,007	1,142	1,255	1,403	1,518	1,651	1,799	1,906
New Hampshire	595	630	663	725	781	801	851	904	949	1,044
New Jersey	6,483	7,024	7,505	8,246	8,891	9,480	10,082	10,779	11,501	11,760
New Mexico	1,220	1,366	1,498	1,611	1,791	1,950	2,123	2,242	2,381	2,582
New York	13,709	14,929	16,123	17,765	19,219	20,608	22,080	23,626	24,936	26,003
North Carolina	5,961	6,694	7,436	8,268	8,911	9,631	10,389	11,072	11,551	12,308
North Dakota	414	463	503	546	542	560	600	634	663	687
Ohio	8,238	9,058	9,751	10,437	11,595	12,415	13,153	13,986	14,769	15,600
Oklahoma	2,042	2,265	2,516	2,757	2,984	3,177	3,450	3,708	3,923	4,156
Oregon	1,844	1,964	2,115	2,311	2,462	2,606	2,741	2,899	3,023	3,144
Pennsylvania	9,958	10,803	11,435	12,623	13,679	14,661	15,429	16,114	16,824	17,358
Rhode Island	707	756	830	929	968	1,047	1,075	1,148	1,169	1,225
South Carolina	3,584	3,953	4,320	4,825	5,243	5,632	6,034	6,410	6,823	7,028
South Dakota	455	475	526	581	654	724	789	832	889	932
Tennessee	4,176	4,609	4,899	5,493	5,952	6,355	6,748	7,163	7,539	7,929
Texas	13,784	15,429	16,900	18,687	20,284	22,097	23,758	25,440	27,223	28,927
Utah	900	963	1,102	1,191	1,314	1,378	1,438	1,567	1,673	1,789
Vermont	288	302	323	356	401	443	482	519	543	580
Virginia	5,217	5,838	6,313	6,747	7,410	7,796	8,556	9,153	9,697	10,051
Washington	3,042	3,267	3,545	3,875	4,176	4,445	4,692	5,001	5,278	5,591
West Virginia	1,228	1,333	1,415	1,524	1,658	1,693	1,871	2,017	2,147	2,317
Wisconsin	3,576	3,937	4,223	4,617	4,921	5,279	5,600	5,960	6,262	6,472
Wyoming	217	225	243	262	287	311	336	355	384	414
American Samoa	24	31	30	28	33	39	40	35	49	59
Guam	80	103	118	129	156	185	216	224	245	255
Puerto Rico	2,228	2,486	2,647	2,915	3,072	3,325	3,506	3,664	3,802	3,932
Saipan	15	21	24	24	36	44	52	71	78	86
Virgin Islands	62	73	74	84	97	113	129	140	146	140
Foreign	177	215	253	303	318	343	360	380	392	401
Unknown	2,772	3,359	4,334	8,831	8,120	6,750	3,124	2,568	2,319	2,175
All	199,951	220,434	239,633	266,888	288,136	308,074	325,342	344,603	361,921	378,862

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.
 *Values for cells with fewer than 10 patients are suppressed.

Table B.11 (continued)

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients*patients alive on December 31 of each year*

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	768	928	1051	1,254	1,464	1,710	1,979	2,124	2,295	2,537
Alaska	35	45	58	106	192	190	184	135	146	139
Arizona	1040	1,255	1,432	1,643	1,862	2,043	2,300	2,486	2,645	2,833
Arkansas	398	448	491	591	716	832	922	966	1018	1084
California	5,980	6,760	7,433	8,556	9,614	10,861	12,189	13,228	14,000	14,987
Colorado	588	689	795	869	936	1042	1,150	1,247	1,329	1,419
Connecticut	603	669	724	833	951	1047	1,192	1,229	1,257	1,368
Delaware	163	180	195	224	248	270	305	331	365	412
District of Columbia	243	293	310	310	341	415	455	459	498	517
Florida	2,616	3,063	3,376	3,786	4,124	4,812	5,390	5,819	6,119	6,452
Georgia	1,519	1,785	1,994	2,316	2,661	3,097	3,403	3,743	4,060	4,344
Hawaii	380	415	495	586	647	701	770	811	843	937
Idaho	156	176	199	228	243	281	322	354	400	410
Illinois	2,157	2,370	2,595	3,007	3,511	3,985	4,398	4,811	5,260	5,584
Indiana	976	1,146	1,224	1,247	1,529	1,740	1,940	2,180	2,364	2,520
Iowa	437	525	585	663	729	816	861	935	1020	1073
Kansas	441	488	512	604	653	724	802	910	983	1033
Kentucky	579	682	743	735	899	1038	1,160	1,286	1,406	1,514
Louisiana	1042	1,241	1,335	1,492	1,707	1,985	2,274	2,531	2,716	2,873
Maine	137	151	173	202	236	262	301	339	342	381
Maryland	1080	1,250	1,359	1,454	1,669	1,890	2,175	2,386	2,547	2,590
Massachusetts	863	1046	1,130	1,308	1,466	1,623	1,794	1,919	1,917	1,997
Michigan	1,894	2,198	2,411	2,805	3,156	3,687	4,018	4,362	4,544	4,892
Minnesota	944	1018	1,125	1,218	1,308	1,396	1,510	1,615	1,681	1,759
Mississippi	579	684	776	928	1072	1,238	1,384	1,536	1,650	1,708
Missouri	992	1,127	1,286	1,478	1,671	1,841	2,055	2,282	2,400	2,550
Montana	168	186	201	221	264	281	307	322	345	375
Nebraska	305	359	404	440	516	552	600	639	692	730
Nevada	201	230	274	322	386	423	487	564	618	665
New Hampshire	139	148	153	177	202	212	241	264	273	299
New Jersey	1,596	1,767	1,906	2,231	2,581	2,899	3,187	3,538	3,826	3,910
New Mexico	456	552	633	703	806	922	1025	1,106	1,204	1,360
New York	3,174	3,623	3,953	4,437	5,125	5,901	6,639	7,255	7,824	8,272
North Carolina	1,509	1,781	2,000	2,363	2,662	3,075	3,471	3,835	4,034	4,373
North Dakota	146	172	182	193	195	195	215	238	228	242
Ohio	2,174	2,491	2,725	2,972	3,461	3,906	4,368	4,877	5,257	5,655
Oklahoma	661	762	869	966	1096	1,177	1,344	1,494	1,614	1,698
Oregon	482	525	569	648	720	800	887	918	976	1008
Pennsylvania	2,500	2,840	2,996	3,417	3,940	4,319	4,728	5,079	5,356	5,616
Rhode Island	144	169	185	214	234	282	312	356	359	367
South Carolina	911	1049	1,159	1,348	1,514	1,723	1,884	2,132	2,343	2,442
South Dakota	151	179	205	227	264	296	325	333	377	390
Tennessee	889	1064	1,183	1,412	1,653	1,857	2,053	2,238	2,378	2,554
Texas	4,328	4,979	5,598	6,428	7,282	8,296	9,277	10,192	11,064	12,014
Utah	313	336	394	444	510	537	564	605	645	691
Vermont	74	80	83	103	126	142	157	176	189	195
Virginia	1,221	1,446	1,592	1,764	1,983	2,213	2,609	2,893	3,142	3,330
Washington	815	938	1045	1,169	1,278	1,400	1,563	1,679	1,788	1,906
West Virginia	313	379	377	430	493	538	635	708	792	908
Wisconsin	1051	1,196	1,285	1,410	1,537	1,671	1,839	1,976	2,081	2,107
Wyoming	62	58	72	86	107	117	131	138	149	163
American Samoa	11	13	11	12	15	19	18	17	25	34
Guam	32	43	51	54	77	98	116	122	141	135
Puerto Rico	746	890	934	1,062	1,127	1,260	1,369	1,462	1,584	1,641
Saipan	*	*	*	10	18	22	27	41	45	53
Virgin Islands	*	*	13	15	25	37	46	52	59	53
Foreign	14	15	11	25	20	21	18	17	22	19
Unknown	186	321	527	1,158	1,067	806	280	162	110	55
All	51,393	59,239	65,405	74,904	84,889	95,523	105,955	115,452	123,345	131,173

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table B.11 (continued)

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients*patients alive on December 31 of each year*

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	3,217	3,449	3,665	3,906	4,122	4,428	4,652	4,799	4,900	5,092
Alaska	143	165	176	296	440	417	350	257	254	282
Arizona	1,924	2,097	2,277	2,400	2,558	2,744	2,911	3,082	3,273	3,380
Arkansas	1,336	1,422	1,563	1,748	1,882	1,959	2,076	2,163	2,241	2,295
California	15,526	16,761	18,087	19,607	20,958	22,359	23,538	24,773	25,646	26,754
Colorado	1,284	1,406	1,523	1,675	1,754	1,855	1,976	2,120	2,210	2,266
Connecticut	1,820	1,951	2,059	2,235	2,341	2,487	2,561	2,657	2,772	2,860
Delaware	453	534	582	623	667	696	723	732	766	764
District of Columbia	800	871	942	986	1082	1,097	1,166	1,201	1,265	1,295
Florida	8,606	9,430	10,154	10,822	11,589	12,354	12,908	13,415	13,759	14,142
Georgia	4,744	5,242	5,677	6,230	6,653	6,979	7,304	7,636	7,992	8,451
Hawaii	650	695	747	813	846	890	960	992	1039	1075
Idaho	395	414	444	486	519	560	604	621	675	686
Illinois	7,531	8,112	8,816	9,473	9,906	10,375	10,820	11,346	11,768	12,125
Indiana	2,992	3,261	3,564	3,791	4,050	4,217	4,427	4,661	4,846	5,117
Iowa	1,418	1,531	1,604	1,707	1,729	1,812	1,883	1,969	2,095	2,153
Kansas	1,210	1,301	1,344	1,433	1,521	1,589	1,718	1,743	1,816	1,852
Kentucky	1,926	2,125	2,295	2,380	2,566	2,664	2,793	2,906	3,015	3,101
Louisiana	3,017	3,258	3,507	3,792	4,100	4,248	4,545	4,764	5,065	5,265
Maine	503	536	588	644	701	735	770	812	836	859
Maryland	3,184	3,478	3,793	4,123	4,564	4,680	4,930	5,194	5,465	5,831
Massachusetts	3,157	3,393	3,664	3,915	4,104	4,266	4,473	4,686	4,695	4,833
Michigan	5,131	5,614	6,106	6,607	7,050	7,525	7,837	8,220	8,489	8,839
Minnesota	2,067	2,270	2,425	2,686	2,852	3,051	3,211	3,343	3,502	3,667
Mississippi	1,969	2,120	2,303	2,557	2,709	2,883	3,050	3,182	3,306	3,419
Missouri	3,055	3,241	3,470	3,718	3,928	4,157	4,291	4,508	4,743	4,863
Montana	321	334	371	397	424	443	476	496	533	537
Nebraska	693	777	803	901	925	953	1026	1,077	1,135	1,189
Nevada	598	667	733	820	869	980	1031	1,087	1,181	1,241
New Hampshire	456	482	510	548	579	589	610	640	676	745
New Jersey	4,887	5,257	5,599	6,015	6,310	6,581	6,895	7,241	7,675	7,850
New Mexico	764	814	865	908	985	1028	1,098	1,136	1,177	1,222
New York	10,535	11,306	12,170	13,328	14,094	14,707	15,441	16,371	17,112	17,731
North Carolina	4,452	4,913	5,436	5,905	6,249	6,556	6,918	7,237	7,517	7,935
North Dakota	268	291	321	353	347	365	385	396	435	445
Ohio	6,064	6,567	7,026	7,465	8,134	8,509	8,785	9,109	9,512	9,945
Oklahoma	1,381	1,503	1,647	1,791	1,888	2,000	2,106	2,214	2,309	2,458
Oregon	1,362	1,439	1,546	1,663	1,742	1,806	1,854	1,981	2,047	2,136
Pennsylvania	7,458	7,963	8,439	9,206	9,739	10,342	10,701	11,035	11,468	11,742
Rhode Island	563	587	645	715	734	765	763	792	810	858
South Carolina	2,673	2,904	3,161	3,477	3,729	3,909	4,150	4,278	4,480	4,586
South Dakota	304	296	321	354	390	428	464	499	512	542
Tennessee	3,287	3,545	3,716	4,081	4,299	4,498	4,695	4,925	5,161	5,375
Texas	9,456	10,450	11,302	12,259	13,002	13,801	14,481	15,248	16,159	16,913
Utah	587	627	708	747	804	841	874	962	1028	1,098
Vermont	214	222	240	253	275	301	325	343	354	385
Virginia	3,996	4,392	4,721	4,983	5,427	5,583	5,947	6,260	6,555	6,721
Washington	2,227	2,329	2,500	2,706	2,898	3,045	3,129	3,322	3,490	3,685
West Virginia	915	954	1038	1,094	1,165	1,155	1,236	1,309	1,355	1,409
Wisconsin	2,525	2,741	2,938	3,207	3,384	3,608	3,761	3,984	4,181	4,365
Wyoming	155	167	171	176	180	194	205	217	235	251
American Samoa	13	18	19	16	18	20	22	18	24	25
Guam	48	60	67	75	79	87	100	102	104	120
Puerto Rico	1,482	1,596	1,713	1,853	1,945	2,065	2,137	2,202	2,218	2,291
Saipan	*	14	16	14	18	22	25	30	33	33
Virgin Islands	57	64	61	69	72	76	83	88	87	87
Foreign	163	200	242	278	298	322	342	363	370	382
Unknown	2,586	3,038	3,807	7,673	7,053	5,944	2,844	2,406	2,209	2,120
All	148,558	161,195	174,228	191,984	203,247	212,551	219,387	229,151	238,576	247,689

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

Table B.12

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped*patients alive on December 31 of each year*

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	3,981	4,372	4,708	5,150	5,576	6,130	6,624	6,915	7,182	7,608
Alaska	177	209	233	385	602	578	521	390	396	417
Arizona	2,943	3,328	3,677	3,996	4,362	4,715	5,132	5,477	5,813	6,081
Arkansas	1,734	1,870	2,053	2,339	2,597	2,790	2,993	3,121	3,244	3,356
California	21,164	23,118	24,986	27,506	29,688	32,009	34,232	36,537	38,242	40,202
Colorado	1,861	2,084	2,305	2,528	2,667	2,870	3,091	3,326	3,503	3,651
Connecticut	2,416	2,613	2,775	3,056	3,272	3,504	3,710	3,837	3,961	4,145
Delaware	613	711	773	842	910	959	1,018	1,051	1,121	1,167
District of Columbia	1,029	1,147	1,234	1,277	1,397	1,482	1,587	1,626	1,729	1,772
Florida	11,193	12,467	13,506	14,570	15,627	17,045	18,153	19,070	19,678	20,369
Georgia	6,260	7,020	7,665	8,534	9,290	10,040	10,675	11,330	11,986	12,687
Hawaii	998	1,081	1,211	1,370	1,461	1,542	1,674	1,751	1,823	1,951
Idaho	549	586	638	709	758	837	920	970	1,069	1,091
Illinois	9,271	10,065	10,993	12,045	12,953	13,878	14,711	15,630	16,514	17,157
Indiana	3,961	4,398	4,782	5,031	5,559	5,931	6,341	6,813	7,171	7,585
Iowa	1,849	2,050	2,183	2,362	2,446	2,616	2,728	2,887	3,098	3,211
Kansas	1,648	1,787	1,854	2,033	2,158	2,289	2,482	2,611	2,760	2,852
Kentucky	2,501	2,803	3,034	3,111	3,459	3,693	3,942	4,181	4,412	4,600
Louisiana	4,056	4,496	4,839	5,277	5,795	6,221	6,808	7,280	7,762	8,110
Maine	636	683	757	842	932	992	1,067	1,148	1,175	1,237
Maryland	4,258	4,723	5,147	5,567	6,203	6,526	7,047	7,511	7,928	8,318
Massachusetts	3,998	4,413	4,762	5,182	5,514	5,796	6,165	6,489	6,483	6,677
Michigan	7,010	7,793	8,499	9,385	10,176	11,176	11,795	12,517	12,963	13,650
Minnesota	3,003	3,281	3,540	3,889	4,139	4,427	4,693	4,925	5,147	5,377
Mississippi	2,544	2,800	3,075	3,472	3,770	4,114	4,429	4,717	4,955	5,123
Missouri	4,039	4,360	4,748	5,185	5,580	5,978	6,320	6,758	7,112	7,382
Montana	487	518	570	617	684	721	779	813	873	907
Nebraska	997	1,135	1,206	1,339	1,434	1,492	1,609	1,699	1,809	1,905
Nevada	794	892	1,002	1,134	1,244	1,389	1,496	1,629	1,772	1,860
New Hampshire	593	628	660	723	778	799	847	898	942	1,033
New Jersey	6,441	6,979	7,450	8,170	8,785	9,323	9,896	10,534	11,224	11,457
New Mexico	1,205	1,344	1,474	1,579	1,759	1,909	2,081	2,190	2,318	2,511
New York	13,539	14,742	15,915	17,416	18,685	19,943	21,302	22,737	23,943	24,870
North Carolina	5,955	6,687	7,427	8,253	8,888	9,605	10,356	11,022	11,490	12,224
North Dakota	412	461	501	542	539	557	597	633	662	683
Ohio	8,220	9,037	9,727	10,407	11,549	12,351	13,079	13,898	14,682	15,502
Oklahoma	2,040	2,263	2,512	2,749	2,971	3,160	3,423	3,677	3,884	4,096
Oregon	1,837	1,956	2,107	2,304	2,450	2,594	2,728	2,884	3,005	3,124
Pennsylvania	9,924	10,760	11,389	12,556	13,578	14,537	15,292	15,958	16,653	17,153
Rhode Island	702	751	825	922	957	1,035	1,062	1,133	1,151	1,201
South Carolina	3,583	3,952	4,319	4,822	5,233	5,622	6,025	6,400	6,810	7,016
South Dakota	450	470	522	577	651	721	786	830	887	929
Tennessee	4,168	4,601	4,890	5,476	5,930	6,332	6,728	7,142	7,510	7,898
Texas	13,695	15,338	16,801	18,555	19,970	21,592	23,168	24,822	26,602	28,154
Utah	899	962	1,098	1,187	1,305	1,368	1,425	1,553	1,660	1,774
Vermont	287	302	322	355	400	442	481	518	542	579
Virginia	5,202	5,823	6,294	6,724	7,361	7,740	8,485	9,068	9,603	9,933
Washington	3,031	3,256	3,530	3,857	4,135	4,404	4,654	4,958	5,239	5,549
West Virginia	1,227	1,332	1,414	1,523	1,655	1,689	1,869	2,014	2,146	2,314
Wisconsin	3,567	3,928	4,212	4,605	4,908	5,264	5,584	5,940	6,241	6,434
Wyoming	217	224	241	260	286	309	333	352	381	406
All	193,164	212,599	230,385	252,295	273,026	293,036	312,943	332,170	349,256	365,288

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded.

Table B.12 (continued)

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped*patients alive on December 31 of each year*

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	768	928	1,051	1,254	1,463	1,708	1,976	2,123	2,295	2,533
Alaska	35	44	57	103	185	183	179	134	144	137
Arizona	1,035	1,248	1,421	1,621	1,840	2,012	2,265	2,449	2,603	2,777
Arkansas	398	448	491	591	715	832	921	963	1,011	1,077
California	5,923	6,673	7,305	8,377	9,320	10,395	11,583	12,662	13,503	14,451
Colorado	588	689	794	868	929	1,031	1,132	1,228	1,311	1,402
Connecticut	603	669	724	831	947	1,039	1,179	1,216	1,240	1,341
Delaware	163	180	194	223	247	268	300	325	361	409
District of Columbia	243	293	310	310	340	412	452	456	496	513
Florida	2,615	3,062	3,375	3,781	4,108	4,777	5,341	5,762	6,046	6,362
Georgia	1,519	1,783	1,993	2,313	2,657	3,090	3,397	3,729	4,044	4,313
Hawaii	374	411	488	579	636	681	750	791	820	913
Idaho	156	175	197	226	241	280	320	353	398	408
Illinois	2,155	2,368	2,588	2,998	3,485	3,937	4,332	4,726	5,179	5,503
Indiana	975	1,145	1,223	1,246	1,525	1,729	1,929	2,167	2,345	2,490
Iowa	437	525	585	663	729	814	857	931	1,016	1,069
Kansas	441	488	512	603	645	708	777	885	960	1,016
Kentucky	579	682	743	734	898	1,037	1,158	1,284	1,404	1,511
Louisiana	1,042	1,241	1,335	1,491	1,704	1,982	2,271	2,526	2,712	2,868
Maine	137	151	173	202	235	261	300	339	342	381
Maryland	1,080	1,250	1,359	1,452	1,659	1,876	2,159	2,371	2,525	2,562
Massachusetts	862	1,045	1,129	1,305	1,453	1,592	1,754	1,878	1,872	1,947
Michigan	1,891	2,194	2,407	2,802	3,151	3,680	4,003	4,349	4,533	4,877
Minnesota	942	1,017	1,124	1,216	1,304	1,392	1,504	1,609	1,673	1,743
Mississippi	579	684	776	926	1,071	1,238	1,384	1,536	1,650	1,708
Missouri	991	1,126	1,285	1,475	1,669	1,837	2,050	2,275	2,392	2,541
Montana	168	186	201	221	263	280	305	319	342	372
Nebraska	305	359	404	439	512	543	588	627	680	721
Nevada	201	230	274	321	383	418	476	553	609	654
New Hampshire	139	148	153	177	201	212	241	264	273	298
New Jersey	1,592	1,761	1,899	2,223	2,557	2,848	3,124	3,448	3,714	3,790
New Mexico	452	543	624	690	795	911	1,011	1,089	1,180	1,333
New York	3,166	3,614	3,937	4,390	4,985	5,695	6,367	6,956	7,480	7,886
North Carolina	1,509	1,781	2,000	2,363	2,661	3,071	3,464	3,826	4,022	4,354
North Dakota	144	170	180	189	192	192	212	237	227	241
Ohio	2,172	2,487	2,719	2,966	3,453	3,891	4,346	4,851	5,225	5,621
Oklahoma	661	762	868	964	1,091	1,170	1,329	1,475	1,593	1,667
Oregon	481	524	567	646	718	799	884	915	972	1,006
Pennsylvania	2,499	2,838	2,994	3,414	3,927	4,292	4,691	5,034	5,306	5,553
Rhode Island	143	168	184	213	231	278	308	351	353	360
South Carolina	911	1,049	1,159	1,348	1,513	1,722	1,884	2,132	2,342	2,441
South Dakota	151	178	204	226	264	296	325	333	377	390
Tennessee	888	1,063	1,182	1,410	1,650	1,853	2,049	2,234	2,373	2,548
Texas	4,313	4,962	5,578	6,398	7,156	8,065	9,005	9,911	10,787	11,667
Utah	313	336	394	444	508	534	559	600	641	688
Vermont	74	80	83	103	126	142	157	176	189	195
Virginia	1,221	1,446	1,591	1,763	1,980	2,207	2,596	2,879	3,129	3,311
Washington	812	936	1,042	1,166	1,266	1,383	1,548	1,664	1,777	1,894
West Virginia	313	379	377	430	493	538	635	708	792	907
Wisconsin	1,050	1,195	1,284	1,409	1,533	1,666	1,834	1,969	2,075	2,099
Wyoming	62	58	72	86	107	116	129	136	147	160
All	50,271	57,772	63,609	72,189	81,721	91,913	102,340	111,754	119,480	127,008

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded.

Table B.12 (continued)

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & State: U.S. Only, with Unknowns Dropped*patients alive on December 31 of each year*

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	3,213	3,444	3,657	3,896	4,113	4,422	4,648	4,792	4,887	5,075
Alaska	142	165	176	282	417	395	342	256	252	280
Arizona	1,908	2,080	2,256	2,375	2,522	2,703	2,867	3,028	3,210	3,304
Arkansas	1,336	1,422	1,562	1,748	1,882	1,958	2,072	2,158	2,233	2,279
California	15,241	16,445	17,681	19,129	20,368	21,614	22,649	23,875	24,739	25,751
Colorado	1,273	1,395	1,511	1,660	1,738	1,839	1,959	2,098	2,192	2,249
Connecticut	1,813	1,944	2,051	2,225	2,325	2,465	2,531	2,621	2,721	2,804
Delaware	450	531	579	619	663	691	718	726	760	758
District of Columbia	786	854	924	967	1057	1,070	1,135	1,170	1,233	1,259
Florida	8,578	9,405	10,131	10,789	11,519	12,268	12,812	13,308	13,632	14,007
Georgia	4,741	5,237	5,672	6,221	6,633	6,950	7,278	7,601	7,942	8,374
Hawaii	624	670	723	791	825	861	924	960	1003	1038
Idaho	393	411	441	483	517	557	600	617	671	683
Illinois	7,116	7,697	8,405	9,047	9,468	9,941	10,379	10,904	11,335	11,654
Indiana	2,986	3,253	3,559	3,785	4,034	4,202	4,412	4,646	4,826	5,095
Iowa	1,412	1,525	1,598	1,699	1,717	1,802	1,871	1,956	2,082	2,142
Kansas	1,207	1,299	1,342	1,430	1,513	1,581	1,705	1,726	1,800	1,836
Kentucky	1,922	2,121	2,291	2,377	2,561	2,656	2,784	2,897	3,008	3,089
Louisiana	3,014	3,255	3,504	3,786	4,091	4,239	4,537	4,754	5,050	5,242
Maine	499	532	584	640	697	731	767	809	833	856
Maryland	3,178	3,473	3,788	4,115	4,544	4,650	4,888	5,140	5,403	5,756
Massachusetts	3,136	3,368	3,633	3,877	4,061	4,204	4,411	4,611	4,611	4,730
Michigan	5,119	5,599	6,092	6,583	7,025	7,496	7,792	8,168	8,430	8,773
Minnesota	2,061	2,264	2,416	2,673	2,835	3,035	3,189	3,316	3,474	3,634
Mississippi	1,965	2,116	2,299	2,546	2,699	2,876	3,045	3,181	3,305	3,415
Missouri	3,048	3,234	3,463	3,710	3,911	4,141	4,270	4,483	4,720	4,841
Montana	319	332	369	396	421	441	474	494	531	535
Nebraska	692	776	802	900	922	949	1021	1,072	1,129	1,184
Nevada	593	662	728	813	861	971	1020	1,076	1,163	1,206
New Hampshire	454	480	507	546	577	587	606	634	669	735
New Jersey	4,849	5,218	5,551	5,947	6,228	6,475	6,772	7,086	7,510	7,667
New Mexico	753	801	850	889	964	998	1,070	1,101	1,138	1,178
New York	10,373	11,128	11,978	13,026	13,700	14,248	14,935	15,781	16,463	16,984
North Carolina	4,446	4,906	5,427	5,890	6,227	6,534	6,892	7,196	7,468	7,870
North Dakota	268	291	321	353	347	365	385	396	435	442
Ohio	6,048	6,550	7,008	7,441	8,096	8,460	8,733	9,047	9,457	9,881
Oklahoma	1,379	1,501	1,644	1,785	1,880	1,990	2,094	2,202	2,291	2,429
Oregon	1,356	1,432	1,540	1,658	1,732	1,795	1,844	1,969	2,033	2,118
Pennsylvania	7,425	7,922	8,395	9,142	9,651	10,245	10,601	10,924	11,347	11,600
Rhode Island	559	583	641	709	726	757	754	782	798	841
South Carolina	2,672	2,903	3,160	3,474	3,720	3,900	4,141	4,268	4,468	4,575
South Dakota	299	292	318	351	387	425	461	497	510	539
Tennessee	3,280	3,538	3,708	4,066	4,280	4,479	4,679	4,908	5,137	5,350
Texas	9,382	10,376	11,223	12,157	12,814	13,527	14,163	14,911	15,815	16,487
Utah	586	626	704	743	797	834	866	953	1019	1,086
Vermont	213	222	239	252	274	300	324	342	353	384
Virginia	3,981	4,377	4,703	4,961	5,381	5,533	5,889	6,189	6,474	6,622
Washington	2,219	2,320	2,488	2,691	2,869	3,021	3,106	3,294	3,462	3,655
West Virginia	914	953	1037	1,093	1,162	1,151	1,234	1,306	1,354	1,407
Wisconsin	2,517	2,733	2,928	3,196	3,375	3,598	3,750	3,971	4,166	4,335
Wyoming	155	166	169	174	179	193	204	216	234	246
All	142,893	154,827	166,776	180,106	191,305	201,123	210,603	220,416	229,776	238,280

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded.

Table B.13

Point Prevalent Rates of Reported ESRD: by Diabetic Status & State*per million population, patients alive on December 31 of each year; adjusted for age, gender, & race*

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	1,031	1,110	1,175	1,269	1,356	1,468	1,558	1,601	1,640	1,718
Alaska	350	392	421	690	1,075	1,010	883	642	638	653
Arizona	802	874	923	960	1,012	1,056	1,115	1,159	1,203	1,238
Arkansas	759	803	868	976	1,069	1,134	1,202	1,239	1,265	1,281
California	736	791	844	918	977	1,032	1,076	1,121	1,145	1,176
Colorado	578	622	664	705	724	759	796	834	855	870
Connecticut	787	843	888	973	1,034	1,097	1,152	1,182	1,204	1,237
Delaware	1,003	1,141	1,196	1,266	1,331	1,372	1,415	1,422	1,479	1,506
District of Columbia	1,855	2,091	2,270	2,394	2,674	2,871	3,082	3,142	3,333	3,418
Florida	898	976	1,034	1,087	1,136	1,209	1,252	1,282	1,293	1,311
Georgia	1,014	1,101	1,168	1,262	1,337	1,402	1,442	1,484	1,524	1,569
Hawaii	973	1,029	1,126	1,249	1,310	1,359	1,447	1,494	1,542	1,640
Idaho	535	553	586	631	658	708	761	784	847	851
Illinois	832	891	961	1,043	1,111	1,179	1,236	1,299	1,358	1,398
Indiana	730	798	858	892	973	1,028	1,087	1,155	1,203	1,260
Iowa	687	753	795	850	874	930	965	1,013	1,078	1,109
Kansas	682	727	745	806	845	889	954	991	1,038	1,063
Kentucky	702	775	828	835	920	970	1,023	1,068	1,110	1,144
Louisiana	1,044	1,137	1,205	1,297	1,402	1,483	1,598	1,685	1,775	1,834
Maine	543	584	641	706	776	817	869	925	936	973
Maryland	980	1,065	1,134	1,201	1,305	1,345	1,420	1,481	1,526	1,561
Massachusetts	709	779	829	893	940	977	1,024	1,064	1,047	1,061
Michigan	780	856	921	1,005	1,075	1,166	1,218	1,280	1,311	1,362
Minnesota	717	769	815	882	924	971	1,013	1,046	1,072	1,097
Mississippi	1,047	1,136	1,224	1,359	1,452	1,559	1,646	1,725	1,784	1,819
Missouri	808	862	928	1,001	1,065	1,128	1,178	1,246	1,297	1,331
Montana	619	646	698	742	809	841	901	930	986	1,011
Nebraska	649	727	769	843	890	917	981	1,028	1,084	1,129
Nevada	658	702	747	798	827	873	890	924	961	965
New Hampshire	563	589	609	658	692	699	728	758	779	838
New Jersey	872	937	988	1,069	1,135	1,188	1,244	1,306	1,373	1,384
New Mexico	842	908	969	1,014	1,102	1,170	1,245	1,282	1,329	1,410
New York	801	866	928	1,008	1,073	1,135	1,199	1,264	1,313	1,345
North Carolina	917	1,010	1,098	1,193	1,260	1,332	1,402	1,459	1,492	1,562
North Dakota	711	769	838	897	875	897	956	1,009	1,048	1,073
Ohio	786	853	908	960	1,058	1,123	1,180	1,244	1,304	1,365
Oklahoma	677	736	806	873	931	978	1,045	1,109	1,153	1,194
Oregon	645	672	705	758	790	821	847	880	903	924
Pennsylvania	860	926	975	1,070	1,151	1,228	1,288	1,338	1,389	1,422
Rhode Island	734	789	859	959	993	1,068	1,091	1,152	1,159	1,197
South Carolina	1,092	1,181	1,264	1,384	1,474	1,553	1,619	1,677	1,744	1,759
South Dakota	665	688	753	822	921	1,006	1,092	1,142	1,206	1,250
Tennessee	880	955	994	1,093	1,160	1,213	1,264	1,318	1,363	1,411
Texas	839	911	971	1,044	1,095	1,154	1,206	1,260	1,316	1,358
Utah	512	534	589	618	661	677	690	738	773	807
Vermont	550	567	593	642	718	780	834	885	910	953
Virginia	888	969	1,026	1,074	1,154	1,191	1,280	1,339	1,387	1,405
Washington	630	659	698	742	779	811	838	874	906	941
West Virginia	709	760	803	860	934	950	1,047	1,122	1,189	1,276
Wisconsin	762	822	868	933	979	1,035	1,086	1,142	1,184	1,203
Wyoming	501	510	540	582	623	666	713	746	793	829
All	806	872	930	1,002	1,068	1,127	1,182	1,234	1,275	1,311

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

Table B.13 (continued)

Point Prevalent Rates of Reported ESRD: by Diabetic Status & State*per million population, patients alive on December 31 of each year; adjusted for age, gender, & race*

DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	199	236	264	310	356	409	465	491	524	572
Alaska	69	85	107	196	341	327	307	222	232	214
Arizona	282	327	356	388	427	451	492	518	539	566
Arkansas	171	191	207	247	294	338	370	383	394	411
California	205	227	246	279	306	335	364	389	404	422
Colorado	183	207	229	242	253	275	293	309	320	333
Connecticut	195	215	232	264	299	325	366	375	377	400
Delaware	266	286	298	333	360	384	418	440	476	529
District of Columbia	439	537	574	583	655	801	881	882	956	989
Florida	212	242	260	284	300	341	370	388	397	409
Georgia	248	281	305	343	384	434	460	489	514	533
Hawaii	365	397	462	537	578	606	651	676	694	766
Idaho	150	165	181	202	208	236	265	285	315	319
Illinois	193	209	225	259	298	334	364	393	426	449
Indiana	179	208	220	221	267	300	331	368	393	413
Iowa	162	192	211	237	260	289	303	327	354	369
Kansas	183	197	206	239	252	275	298	336	361	379
Kentucky	164	189	204	198	240	274	302	328	353	375
Louisiana	269	316	334	369	415	476	535	586	620	648
Maine	117	132	149	170	199	216	245	273	272	300
Maryland	250	283	300	314	350	388	436	468	486	481
Massachusetts	153	185	197	225	249	269	292	308	302	309
Michigan	208	239	260	299	332	384	413	445	458	487
Minnesota	225	238	259	276	291	305	325	342	348	356
Mississippi	239	278	310	363	414	469	515	562	594	607
Missouri	200	224	251	285	320	348	383	420	436	458
Montana	211	231	245	266	314	329	354	365	386	414
Nebraska	201	233	260	277	319	335	359	380	408	428
Nevada	168	179	204	225	254	262	283	314	330	339
New Hampshire	135	142	146	166	180	186	207	223	226	241
New Jersey	215	236	252	291	331	363	393	428	454	458
New Mexico	317	369	412	448	503	563	609	640	677	746
New York	188	213	230	255	287	325	359	387	410	425
North Carolina	231	269	296	342	378	427	470	507	522	556
North Dakota	246	288	310	320	311	310	341	379	359	376
Ohio	207	234	252	273	316	353	392	434	464	495
Oklahoma	220	248	279	306	342	363	407	445	473	486
Oregon	167	178	188	211	231	253	274	279	292	297
Pennsylvania	214	242	254	289	331	361	394	422	443	461
Rhode Island	148	173	188	220	240	287	316	356	355	360
South Carolina	278	315	340	390	428	477	507	559	600	613
South Dakota	223	262	297	323	375	414	454	459	513	525
Tennessee	188	220	239	281	323	356	385	412	431	455
Texas	266	295	323	361	393	432	470	504	534	562
Utah	176	187	212	231	257	264	271	286	299	313
Vermont	147	158	159	190	229	254	274	301	317	319
Virginia	205	238	258	281	309	339	391	425	452	470
Washington	167	187	204	222	237	254	278	293	307	321
West Virginia	180	216	216	245	279	304	356	395	439	500
Wisconsin	226	250	266	286	306	327	356	379	394	392
Wyoming	137	131	162	193	234	251	276	288	306	327
All	210	237	257	287	320	354	387	415	436	456

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded so that rates can be calculated appropriately.

Table B.13 (continued)

Point Prevalent Rates of Reported ESRD: by Diabetic Status & State*per million population, patients alive on December 31 of each year; adjusted for age, gender, & race*

NON-DIABETIC	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Alabama	832	875	912	959	1,000	1,059	1,093	1,109	1,116	1,145
Alaska	281	307	314	494	734	683	575	421	406	439
Arizona	520	546	567	572	585	605	623	641	665	672
Arkansas	588	612	661	728	775	795	832	856	871	870
California	532	564	598	639	671	696	711	732	741	754
Colorado	395	415	435	463	471	484	503	525	535	537
Connecticut	591	627	656	709	736	772	785	807	827	837
Delaware	737	855	898	934	971	988	997	982	1,003	977
District of Columbia	1,416	1,554	1,697	1,811	2,019	2,070	2,201	2,259	2,377	2,429
Florida	686	735	774	803	835	868	882	894	896	902
Georgia	766	820	863	918	953	969	982	995	1,010	1,036
Hawaii	608	632	664	711	732	753	795	818	848	875
Idaho	385	388	405	429	450	472	496	499	531	532
Illinois	639	683	736	784	813	845	873	906	932	949
Indiana	551	591	639	671	706	728	756	788	810	846
Iowa	525	562	583	614	614	641	662	686	725	740
Kansas	499	530	540	567	593	615	656	655	677	684
Kentucky	538	585	624	637	680	696	721	739	757	768
Louisiana	775	821	871	928	987	1,008	1,063	1,100	1,155	1,186
Maine	426	452	492	536	577	601	625	652	663	673
Maryland	730	782	834	887	955	957	984	1,013	1,040	1,081
Massachusetts	556	594	632	668	691	708	732	755	745	752
Michigan	572	617	661	707	743	782	805	835	852	876
Minnesota	491	531	555	606	633	666	689	704	724	741
Mississippi	808	858	914	995	1,039	1,089	1,131	1,162	1,190	1,213
Missouri	608	638	676	716	745	780	795	826	860	873
Montana	407	415	452	476	495	512	547	565	600	598
Nebraska	448	494	509	566	572	583	622	648	677	702
Nevada	490	522	544	574	573	611	607	610	630	625
New Hampshire	428	447	463	492	512	513	521	535	554	597
New Jersey	657	701	736	778	804	825	851	878	919	926
New Mexico	526	539	557	566	600	607	636	642	653	664
New York	613	653	698	753	786	810	840	876	903	920
North Carolina	686	741	802	852	882	905	932	952	970	1,006
North Dakota	465	481	528	577	564	587	616	630	689	697
Ohio	579	619	656	688	743	769	788	810	840	870
Oklahoma	457	488	527	567	589	615	639	664	680	708
Oregon	479	494	518	547	559	568	573	601	611	627
Pennsylvania	646	684	721	781	820	867	893	916	946	961
Rhode Island	586	616	671	739	754	781	775	795	803	837
South Carolina	814	866	924	994	1,046	1,075	1,112	1,118	1,144	1,147
South Dakota	442	426	457	499	545	593	638	683	694	725
Tennessee	692	735	754	812	837	858	879	906	933	956
Texas	573	615	648	683	702	722	736	757	782	796
Utah	336	347	377	388	404	413	418	453	475	495
Vermont	404	410	435	451	489	527	560	583	592	634
Virginia	683	731	768	793	845	852	888	915	935	936
Washington	463	472	494	520	542	557	560	581	599	620
West Virginia	528	545	586	616	655	646	690	727	750	776
Wisconsin	536	572	602	647	673	708	729	763	790	811
Wyoming	364	379	379	388	390	416	437	458	487	502
All	596	635	673	715	748	773	795	818	839	855

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other & unknown are excluded.

Table B.14

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & ESRD Network: All Patients*all patients alive on December 31 of each year*

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	8,838	9,639	10,424	11,552	12,331	13,023	13,725	14,415	14,671	15,321
2 NY	13,923	15,193	16,428	19,067	20,444	21,664	22,452	23,904	25,156	26,250
3 NJ, PR, VI	8,932	9,826	10,636	11,978	12,689	13,338	13,769	14,604	15,456	15,830
4 DE, PA	10,672	11,643	12,347	13,942	14,948	15,944	16,559	17,322	18,091	18,671
5 MD, DC, VA, WV	11,862	13,184	14,252	15,356	16,941	17,783	19,293	20,546	21,764	22,746
6 NC, SC, GA	15,875	17,747	19,510	22,001	23,831	25,671	27,256	28,954	30,493	32,181
7 FL	11,270	12,543	13,588	14,694	15,801	17,257	18,369	19,313	19,968	20,685
8 AL, MS, TN	10,791	11,901	12,846	14,641	15,782	17,006	17,973	18,925	19,792	20,777
9 IN, KY, OH	14,809	16,395	17,704	18,755	20,820	22,239	23,608	25,128	26,495	27,936
10 IL	9,904	10,740	11,754	13,203	14,095	14,924	15,445	16,319	17,167	17,827
11 MI, MN, ND, SD, WI	14,717	16,220	17,601	19,794	21,254	22,937	24,004	25,321	26,357	27,557
12 IA, KS, MO, NE	8,632	9,434	10,100	11,245	11,967	12,701	13,351	14,150	14,983	15,527
13 AR, LA, OK	7,867	8,666	9,445	10,500	11,522	12,324	13,325	14,173	14,990	15,695
14 TX	13,920	15,596	17,169	18,981	20,607	22,367	23,993	25,641	27,420	29,121
15 AZ, CO, NV, NM, UT, WY	8,114	9,097	10,184	11,217	12,159	13,021	13,934	14,878	15,814	16,693
16 AK, ID, MT, OR, WA	6,131	6,566	7,108	7,827	8,420	8,975	9,508	10,057	10,631	11,150
17 N. CA, HI, GUAM, AS	9,623	10,535	11,589	12,853	13,711	14,590	15,673	16,486	17,170	18,089
18 S. CA	13,626	15,083	16,515	18,773	20,357	21,874	22,758	24,113	25,132	26,401
Unknown network	445	426	433	509	457	436	347	354	371	405
All	199,951	220,434	239,633	266,888	288,136	308,074	325,342	344,603	361,921	378,862
DIABETIC										
1 CT, MA, ME, NH, RI, VT	1,963	2,269	2,461	2,863	3,238	3,589	4,007	4,289	4,341	4,608
2 NY	3,183	3,639	3,970	4,533	5,221	5,991	6,669	7,272	7,835	8,278
3 NJ, PR, VI	2,351	2,667	2,854	3,341	3,773	4,230	4,608	5,055	5,470	5,604
4 DE, PA	2,663	3,024	3,192	3,646	4,148	4,544	4,992	5,401	5,715	6,026
5 MD, DC, VA, WV	2,861	3,373	3,641	3,959	4,488	5,061	5,876	6,447	6,983	7,346
6 NC, SC, GA	3,940	4,619	5,162	6,067	6,885	7,935	8,774	9,720	10,441	11,159
7 FL	2,619	3,064	3,377	3,784	4,119	4,806	5,385	5,817	6,120	6,452
8 AL, MS, TN	2,239	2,681	3,015	3,632	4,237	4,843	5,435	5,910	6,331	6,807
9 IN, KY, OH	3,738	4,332	4,708	4,985	5,925	6,711	7,483	8,349	9,031	9,687
10 IL	2,169	2,385	2,611	3,044	3,555	4,024	4,418	4,820	5,264	5,586
11 MI, MN, ND, SD, WI	4,193	4,770	5,222	5,912	6,527	7,302	7,941	8,551	8,940	9,416
12 IA, KS, MO, NE	2,180	2,504	2,798	3,230	3,608	3,959	4,329	4,770	5,099	5,391
13 AR, LA, OK	2,105	2,456	2,700	3,084	3,566	4,033	4,558	5,003	5,352	5,659
14 TX	4,331	4,991	5,650	6,488	7,350	8,346	9,312	10,213	11,082	12,028
15 AZ, CO, NV, NM, UT, WY	2,693	3,181	3,697	4,226	4,757	5,198	5,717	6,175	6,612	7,141
16 AK, ID, MT, OR, WA	1,663	1,874	2,068	2,346	2,607	2,879	3,207	3,395	3,647	3,836
17 N. CA, HI, GUAM, AS	2,635	2,970	3,394	3,943	4,353	4,803	5,373	5,775	6,081	6,518
18 S. CA	3,853	4,425	4,874	5,811	6,527	7,264	7,867	8,487	8,999	9,629
Unknown network	14	15	11	10	*	*	*	*	*	*
All	51,393	59,239	65,405	74,904	84,889	95,523	105,955	115,452	123,345	131,173
NON-DIABETIC										
1 CT, MA, ME, NH, RI, VT	6,875	7,370	7,963	8,689	9,093	9,434	9,718	10,126	10,330	10,713
2 NY	10,740	11,554	12,458	14,534	15,223	15,673	15,783	16,632	17,321	17,972
3 NJ, PR, VI	6,581	7,159	7,782	8,637	8,916	9,108	9,161	9,549	9,986	10,226
4 DE, PA	8,009	8,619	9,155	10,296	10,800	11,400	11,567	11,921	12,376	12,645
5 MD, DC, VA, WV	9,001	9,811	10,611	11,397	12,453	12,722	13,417	14,099	14,781	15,400
6 NC, SC, GA	11,935	13,128	14,348	15,934	16,946	17,736	18,482	19,234	20,052	21,022
7 FL	8,651	9,479	10,211	10,910	11,682	12,451	12,984	13,496	13,848	14,233
8 AL, MS, TN	8,552	9,220	9,831	11,009	11,545	12,163	12,538	13,015	13,461	13,970
9 IN, KY, OH	11,071	12,063	12,996	13,770	14,895	15,528	16,125	16,779	17,464	18,249
10 IL	7,735	8,355	9,143	10,159	10,540	10,900	11,027	11,499	11,903	12,241
11 MI, MN, ND, SD, WI	10,524	11,450	12,379	13,882	14,727	15,635	16,063	16,770	17,417	18,141
12 IA, KS, MO, NE	6,452	6,930	7,302	8,015	8,359	8,742	9,022	9,380	9,884	10,136
13 AR, LA, OK	5,762	6,210	6,745	7,416	7,956	8,291	8,767	9,170	9,638	10,036
14 TX	9,589	10,605	11,519	12,493	13,257	14,021	14,681	15,428	16,338	17,093
15 AZ, CO, NV, NM, UT, WY	5,421	5,916	6,487	6,991	7,402	7,823	8,217	8,703	9,202	9,552
16 AK, ID, MT, OR, WA	4,468	4,692	5,040	5,481	5,813	6,096	6,301	6,662	6,984	7,314
17 N. CA, HI, GUAM, AS	6,988	7,565	8,195	8,910	9,358	9,787	10,300	10,711	11,089	11,571
18 S. CA	9,773	10,658	11,641	12,962	13,830	14,610	14,891	15,626	16,133	16,772
Unknown network	431	411	422	499	452	431	343	351	369	403
All	148,558	161,195	174,228	191,984	203,247	212,551	219,387	229,151	238,576	247,689

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule.

*Values for cells with fewer than 10 patients are suppressed.

Table B.15

Point Prevalent Counts of Reported ESRD Patients, by Diabetic Status & ESRD Network: U.S. Only, with Unknowns Dropped

patients alive on December 31 of each year

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	8,628	9,386	10,096	11,072	11,859	12,571	13,334	14,019	14,228	14,837
2 NY	13,529	14,740	15,907	17,504	18,799	20,036	21,327	22,722	23,908	24,812
3 NJ, PR, VI	6,441	6,972	7,441	8,162	8,798	9,330	9,892	10,513	11,197	11,426
4 DE, PA	10,529	11,463	12,150	13,351	14,345	15,359	16,206	16,965	17,727	18,264
5 MD, DC, VA, WV	11,709	13,008	14,069	15,055	16,586	17,408	18,968	20,201	21,382	22,303
6 NC, SC, GA	15,792	17,653	19,405	21,604	23,416	25,271	27,058	28,748	30,270	31,892
7 FL	11,189	12,461	13,499	14,537	15,593	17,014	18,134	19,052	19,660	20,348
8 AL, MS, TN	10,683	11,762	12,667	14,101	15,285	16,580	17,779	18,763	19,633	20,618
9 IN, KY, OH	14,664	16,224	17,523	18,530	20,551	21,943	23,314	24,818	26,173	27,578
10 IL	9,268	10,062	10,993	12,092	13,016	13,930	14,722	15,616	16,493	17,123
11 MI, MN, ND, SD, WI	14,443	15,934	17,275	19,022	20,458	22,182	23,481	24,865	25,920	27,090
12 IA, KS, MO, NE	8,533	9,332	9,991	10,917	11,625	12,381	13,145	13,955	14,776	15,347
13 AR, LA, OK	7,831	8,629	9,402	10,374	11,380	12,186	13,228	14,074	14,881	15,548
14 TX	13,688	15,329	16,790	18,465	19,915	21,542	23,160	24,798	26,576	28,122
15 AZ, CO, NV, NM, UT, WY	7,913	8,827	9,790	10,686	11,648	12,577	13,565	14,516	15,434	16,268
16 AK, ID, MT, OR, WA	6,078	6,511	7,049	7,727	8,290	8,846	9,403	9,952	10,530	11,044
17 N. CA, HI, GUAM, AS	9,069	9,845	10,722	11,751	12,551	13,354	14,359	15,193	15,895	16,812
18 S. CA	13,064	14,323	15,439	17,126	18,663	20,246	21,484	22,957	24,020	25,224
All	193,051	212,461	230,208	252,076	272,778	292,756	312,559	331,727	348,703	364,656
DIABETIC										
1 CT, MA, ME, NH, RI, VT	1,957	2,261	2,448	2,832	3,198	3,529	3,942	4,224	4,269	4,522
2 NY	3,166	3,616	3,939	4,407	5,003	5,711	6,375	6,958	7,480	7,885
3 NJ, PR, VI	1,593	1,760	1,898	2,222	2,564	2,855	3,127	3,448	3,714	3,789
4 DE, PA	2,661	3,018	3,186	3,624	4,118	4,502	4,949	5,349	5,660	5,959
5 MD, DC, VA, WV	2,856	3,366	3,635	3,952	4,472	5,035	5,842	6,413	6,942	7,293
6 NC, SC, GA	3,938	4,612	5,152	6,028	6,838	7,888	8,751	9,692	10,410	11,108
7 FL	2,615	3,062	3,375	3,771	4,098	4,768	5,337	5,760	6,045	6,360
8 AL, MS, TN	2,236	2,675	3,011	3,596	4,195	4,807	5,413	5,894	6,319	6,792
9 IN, KY, OH	3,728	4,316	4,689	4,961	5,893	6,670	7,437	8,301	8,973	9,617
10 IL	2,157	2,369	2,589	3,008	3,507	3,957	4,345	4,732	5,181	5,503
11 MI, MN, ND, SD, WI	4,178	4,753	5,199	5,851	6,462	7,247	7,895	8,513	8,904	9,369
12 IA, KS, MO, NE	2,174	2,498	2,787	3,178	3,553	3,900	4,270	4,716	5,046	5,347
13 AR, LA, OK	2,101	2,451	2,694	3,050	3,521	3,994	4,526	4,968	5,317	5,614
14 TX	4,311	4,960	5,576	6,370	7,145	8,057	9,011	9,911	10,788	11,668
15 AZ, CO, NV, NM, UT, WY	2,650	3,104	3,581	4,035	4,579	5,035	5,582	6,058	6,494	7,017
16 AK, ID, MT, OR, WA	1,654	1,866	2,059	2,322	2,574	2,842	3,177	3,367	3,621	3,812
17 N. CA, HI, GUAM, AS	2,533	2,818	3,173	3,631	3,986	4,395	4,910	5,311	5,628	6,070
18 S. CA	3,761	4,262	4,613	5,342	6,013	6,718	7,422	8,110	8,661	9,274
All	50,269	57,767	63,604	72,180	81,719	91,910	102,311	111,725	119,452	126,999
NON-DIABETIC										
1 CT, MA, ME, NH, RI, VT	6,671	7,125	7,648	8,240	8,661	9,042	9,392	9,795	9,959	10,315
2 NY	10,363	11,124	11,968	13,097	13,796	14,325	14,952	15,764	16,428	16,927
3 NJ, PR, VI	4,848	5,212	5,543	5,940	6,234	6,475	6,765	7,065	7,483	7,637
4 DE, PA	7,868	8,445	8,964	9,727	10,227	10,857	11,257	11,616	12,067	12,305
5 MD, DC, VA, WV	8,853	9,642	10,434	11,103	12,114	12,373	13,126	13,788	14,440	15,010
6 NC, SC, GA	11,854	13,041	14,253	15,576	16,578	17,383	18,307	19,056	19,860	20,784
7 FL	8,574	9,399	10,124	10,766	11,495	12,246	12,797	13,292	13,615	13,988
8 AL, MS, TN	8,447	9,087	9,656	10,505	11,090	11,773	12,366	12,869	13,314	13,826
9 IN, KY, OH	10,936	11,908	12,834	13,569	14,658	15,273	15,877	16,517	17,200	17,961
10 IL	7,111	7,693	8,404	9,084	9,509	9,973	10,377	10,884	11,312	11,620
11 MI, MN, ND, SD, WI	10,265	11,181	12,076	13,171	13,996	14,935	15,586	16,352	17,016	17,721
12 IA, KS, MO, NE	6,359	6,834	7,204	7,739	8,072	8,481	8,875	9,239	9,730	10,000
13 AR, LA, OK	5,730	6,178	6,708	7,324	7,859	8,192	8,702	9,106	9,564	9,934
14 TX	9,377	10,369	11,214	12,095	12,770	13,485	14,149	14,887	15,788	16,454
15 AZ, CO, NV, NM, UT, WY	5,263	5,723	6,209	6,651	7,069	7,542	7,983	8,458	8,940	9,251
16 AK, ID, MT, OR, WA	4,424	4,645	4,990	5,405	5,716	6,004	6,226	6,585	6,909	7,232
17 N. CA, HI, GUAM, AS	6,536	7,027	7,549	8,120	8,565	8,959	9,449	9,882	10,267	10,742
18 S. CA	9,303	10,061	10,826	11,784	12,650	13,528	14,062	14,847	15,359	15,950
All	142,782	154,694	166,604	179,896	191,059	200,846	210,248	220,002	229,251	237,657

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; other, unknown, & unknown network are excluded.

Table B.16

Point Prevalent Rates of Reported ESRD: by Diabetic Status & ESRD Network*patients alive on December 31 of each year*

ALL	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
1 CT, MA, ME, NH, RI, VT	694	751	799	868	921	965	1,011	1,051	1,051	1,079
2 NY	801	866	928	1,013	1,080	1,141	1,200	1,263	1,311	1,342
3 NJ	872	936	986	1,068	1,136	1,189	1,244	1,303	1,370	1,380
4 DE, PA	867	937	987	1,077	1,150	1,226	1,287	1,340	1,391	1,423
5 MD, DC, VA, WV	932	1,017	1,080	1,138	1,234	1,274	1,365	1,427	1,481	1,514
6 NC, SC, GA	991	1,080	1,159	1,259	1,334	1,404	1,462	1,513	1,555	1,602
7 FL	898	976	1,034	1,084	1,133	1,206	1,251	1,281	1,292	1,310
8 AL, MS, TN	968	1,047	1,106	1,212	1,292	1,377	1,449	1,504	1,550	1,606
9 IN, KY, OH	753	822	878	917	1,008	1,066	1,122	1,182	1,235	1,289
10 IL	831	891	961	1,047	1,117	1,183	1,237	1,298	1,357	1,395
11 MI, MN, ND, SD, WI	753	818	874	950	1,007	1,077	1,128	1,181	1,215	1,251
12 IA, KS, MO, NE	733	791	838	905	953	1,006	1,057	1,111	1,165	1,198
13 AR, LA, OK	852	921	990	1,079	1,167	1,232	1,319	1,385	1,444	1,485
14 TX	838	910	970	1,039	1,092	1,152	1,206	1,259	1,315	1,356
15 AZ, CO, NV, NM, UT, WY	679	730	778	819	864	903	945	984	1,019	1,049
16 AK, ID, MT, OR, WA	608	635	671	718	755	789	822	853	886	913
17 N. CA, HI	779	830	889	959	1,008	1,049	1,100	1,138	1,165	1,206
18 S. CA	722	779	830	911	980	1,042	1,079	1,124	1,148	1,177
All	806	872	930	1,002	1,068	1,127	1,182	1,234	1,275	1,311
DIABETIC										
1 CT, MA, ME, NH, RI, VT	158	182	194	223	249	271	299	317	315	329
2 NY	188	213	230	256	288	326	360	387	410	425
3 NJ	215	236	252	291	332	364	393	428	454	458
4 DE, PA	216	244	257	290	328	358	392	422	444	465
5 MD, DC, VA, WV	226	262	279	298	332	369	420	453	481	496
6 NC, SC, GA	247	283	308	352	391	440	474	510	535	558
7 FL	212	242	260	283	300	340	370	388	397	409
8 AL, MS, TN	203	238	263	309	355	400	442	472	499	529
9 IN, KY, OH	191	218	235	245	289	324	358	395	423	449
10 IL	193	209	225	260	300	336	365	393	426	449
11 MI, MN, ND, SD, WI	218	244	263	292	318	352	379	404	417	433
12 IA, KS, MO, NE	188	212	234	263	292	317	344	376	398	417
13 AR, LA, OK	228	262	284	319	362	405	452	490	516	536
14 TX	266	295	323	359	393	432	470	504	534	562
15 AZ, CO, NV, NM, UT, WY	227	257	285	309	340	363	390	411	429	452
16 AK, ID, MT, OR, WA	163	180	194	214	233	253	277	289	305	315
17 N. CA, HI	218	238	264	297	321	347	377	398	412	435
18 S. CA	206	231	247	284	316	346	373	398	414	432
All	210	237	257	287	320	354	387	415	436	456
NON-DIABETIC										
1 CT, MA, ME, NH, RI, VT	537	569	604	646	672	694	712	734	736	750
2 NY	613	653	698	758	792	815	841	875	901	917
3 NJ	657	700	735	778	804	825	850	876	915	923
4 DE, PA	651	693	730	787	822	868	895	918	947	958
5 MD, DC, VA, WV	706	755	802	839	902	906	944	974	1,000	1,018
6 NC, SC, GA	743	797	851	907	943	964	988	1,002	1,020	1,044
7 FL	686	734	773	801	833	866	881	893	894	901
8 AL, MS, TN	765	809	843	903	937	978	1,008	1,032	1,051	1,076
9 IN, KY, OH	562	604	643	671	719	742	764	787	811	839
10 IL	639	682	736	787	816	848	873	905	931	946
11 MI, MN, ND, SD, WI	536	575	611	658	690	726	749	777	798	818
12 IA, KS, MO, NE	545	579	604	641	661	688	713	736	767	780
13 AR, LA, OK	624	659	706	760	805	827	866	896	928	949
14 TX	573	615	647	680	699	720	736	755	781	794
15 AZ, CO, NV, NM, UT, WY	452	473	493	509	523	541	555	573	590	597
16 AK, ID, MT, OR, WA	445	455	477	504	521	536	544	564	582	598
17 N. CA, HI	560	591	625	662	686	703	723	740	752	771
18 S. CA	516	548	583	627	665	696	706	727	734	744
All	596	635	673	715	748	773	795	818	839	855

The point prevalent cohorts and associated modalities are determined on December 31 of each calendar year without applying the 60-day stable modality rule. U.S. only; unknown age, gender, & race; "other" & "unknown" are excluded so that values can be calculated appropriately.

